

STIC-Biotech/ChemLib

From: Steadman, David (AU1652)
Sent: Wednesday, May 30, 2001 8:03 AM
To: STIC-Biotech/ChemLib
Subject: 09/526,193 SEQ SEARCH

NAME: David Steadman
AU: 1652
Date: 05/30/01
Room: 10D-04
Mailbox #: 10C-01 M3
Serial #: 09/526,193

Please search the following sequence(s) in commercial databases:

Amino Acid

Amino acids 1-60 of SEQ ID NO:1 against amino acid databases
Amino acids 1-60 of SEQ ID NO:1 against nucleic acid databases

Thank you,
David Steadman

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 13:04:34 ; Search time 49.05 Seconds
(without alignments)
143.374 Million cell updates/sec

Title: us-09-526-193a-1_copy_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKLNLTFRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 374700 seqs, 117207915 residues

Total number of hits satisfying chosen parameters: 374700

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_15:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phase:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_unclassified:*
- 13: sp_vertebrate:*
- 14: sp_virus:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	334	100.0	70	Q9NS76	Q9ns76 homo sapien
2	334	100.0	100	Q9NP93	Q9np93 homo sapien
3	334	100.0	2261	Q9NQV4	Q9nqv4 homo sapien
4	230	68.9	2146	Q9NR73	Q9nr73 homo sapien
5	185	55.4	2310	Q35600	Q35600 mus musculus
6	179	53.6	2281	Q02698	Q02698 bos taurus
7	100	29.9	602	Q9N403	Q9n403 caenorhabdi
8	78	23.4	1713	Q9VRG4	Q9vrg4 drosophila
9	71.5	21.4	707	Q9T050	Q9t050 arabidopsis
10	65.5	19.6	307	Q9PVW2	Q9pvw2 oryza lat
11	65.5	19.6	307	Q9PVW1	Q9pvw1 oryza lat
12	61.5	18.4	129	Q9ZPB9	Q9zpb9 crawfurdi
13	61.5	18.4	2272	Q9VZS7	Q9vzs7 drosophila
14	61	18.3	218	Q9NF52	Q9nf52 drosophila
15	60.5	18.1	598	Q82747	Q82747 arabidopsis
16	60	18.0	1802	Q9TXV8	Q9txv8 caenorhabdi
17	60	18.0	1880	Q9IBF1	Q9ibf1 takifugu pa
18	59.5	17.8	383	Q82729	Q82729 borago offi
19	59.5	17.8	473	Q94789	Q94789 trichostrom

20	59.5	17.8	512	5	P92039	P92039 haemochus
21	58.5	17.5	426	5	O96760	O96760 ascaris suu
22	58.5	17.5	586	10	Q9SNT3	Q9snt3 oryza sativ
23	58	17.4	250	2	Q9RSP1	Q9rsp1 deinococcus
24	57	17.1	1717	13	Q90519	Q90519 fugu rubrip
25	56.5	16.9	272	4	Q9UKB8	Q9ukb8 homo sapien
26	56.5	16.9	383	10	Q9LLL7	Q9lll7 sesamum ind
27	56.5	16.9	870	4	O60309	O60309 homo sapien
28	56.5	16.9	1400	5	Q20766	Q20766 caenorhabdi
29	56.5	16.9	1977	4	Q15858	Q15858 homo sapien
30	56.5	16.9	3268	3	Q03280	Q03280 saccharomyc
31	56	16.8	373	4	Q9NS66	Q9ns66 homo sapien
32	56	16.8	373	11	Q9JH2	Q9jjh2 rattus norv
33	56	16.8	403	10	Q9LPG9	Q9lpg9 arabidopsis
34	56	16.8	512	2	Q9JVA8	Q9jva8 neisseria m
35	56	16.8	524	2	Q9K0A2	Q9k0a2 neisseria m
36	56	16.8	830	10	O65482	O65482 arabidopsis
37	56	16.8	1215	2	Q92771	Q9z771 chlamydia p
38	56	16.8	1215	2	Q9JS99	Q9js99 chlamydia p
39	55.5	16.6	372	5	Q18933	Q18933 caenorhabdi
40	55.5	16.6	378	10	O24499	O24499 hellanthus
41	55.5	16.6	485	2	O53300	O53300 mycobacteri
42	55.5	16.6	706	5	Q9XUG5	Q9xug5 caenorhabdi
43	55.5	16.6	837	4	O75173	O75173 homo sapien
44	55.5	16.6	837	4	Q9UN83	Q9un83 homo sapien
45	55	16.5	276	11	Q60828	Q60828 mus musculu

ALIGNMENTS

RESULT 1
Q9NS76 PRELIMINARY; PRT; 70 AA.
ID Q9NS76
AC Q9NS76;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-OCT-2000 (Tremblrel. 15, Last annotation update)
DE ABC1 (FRAGMENT).
GN ABC1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=PLACENTA;
RA Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T.,
RA Shioda S., Ueda K., Inagaki N.;
RT "Cloning, characterization, and tissue distribution of the ABC
RT transporter ABC2";
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB037924; BAB07875.1; -
FT NON_TER 70
SQ SEQUENCE 70 AA; 8383 MW; C6DBDEF854F034F CRC64;

Query Match 100.0%; Score 334; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 1.1e-34;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLKLNLTFRRTQTCOLLEVAWPLFIILLISVRLSPYPYEQHECHFPNKA 60
|||||
DB 1 MACWPQLRLLLKLNLTFRRTQTCOLLEVAWPLFIILLISVRLSPYPYEQHECHFPNKA 60
|||||

RESULT 2
Q9NP93 PRELIMINARY; PRT; 100 AA.
ID Q9NP93
AC Q9NP93;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-OCT-2000 (Tremblrel. 15, Last annotation update)

DE ATP BINDING CASSETTE TRANSPORTER 1 (FRAGMENT).

GN ABCA1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=PLACENTA;
RA Pullinger C.R., Hakamata H., Duchateau P.N., Eng C., Aouizerat B.E.,
RA Fielding C.J., Kane J.P.;
RT "Analysis of hABC1 gene 5' end: additional peptide sequence, promoter
region, and four polymorphisms";
RL Biochem. Biophys. Res. Commun. 271:0-0(2000).
DR EMBL: AF258626; AAF69516.1; -.
DR EMBL: AF258624; AAF69516.1; JOINED.
DR EMBL: AF258625; AAF69516.1; JOINED.
DR EMBL: AF258627; AAF69513.1; -.
FT NON-TER 100 100
SQ SEQUENCE 100 AA; 11530 MW; ABEBA02D542CE853 CRC64;

Query Match 100.0%; Score 334; DB 4; Length 100;

Best Local Similarity 100.0%; Pred. No. 1.5e-34;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

DB 1 MACWPQLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

RESULT 3

ID Q9NOV4 PRELIMINARY; PRT; 2261 AA.

AC Q9NOV4;

DT 01-OCT-2000 (TReMBLrel. 15, Created)

DT 01-OCT-2000 (TReMBLrel. 15, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE ABCA1.

GN ABCA1.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Santamarina-Pojo S., Peterson K.M., Knapper C.L., Qiu Y.,

RA Freeman L.A., Cheng J.-F., Osorio J., Remaley A.T., Yang X.-P.,

RA Haudenschild C.C., Prades C., Chimini G., Blackmon E.E.,

RA Francois T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P.,

RA Fredrickson D.S., Brewer H.B. Jr.;

RT "Complete genomic sequence of the human ABCA1 gene: Analysis of the

RT human and mouse ATP-binding cassette A promoter";

RL Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).

DR EMBL: AF275948; AAF86276.1; -.
SQ SEQUENCE 2261 AA; 254324 MW; BA27D9B217ACAA33 CRC64;

Query Match

Best Local Similarity 100.0%; Score 334; DB 4; Length 2261;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

DB 1 MACWPQLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

RESULT 4

ID Q9NR73

AC Q9NR73 PRELIMINARY; PRT; 2146 AA.

DT 01-OCT-2000 (TReMBLrel. 15, Created)

DT 01-OCT-2000 (TReMBLrel. 15, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE MACROPHAGE ABC TRANSPORTER.

GN ABCA7.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Kaminski W.E., Orso E., Diederich W., Klucken J., Drobnik W.,

RA Schmitz G.;

RT "Identification of a Novel Human Sterol-Sensitive ATP-Binding Cassette

RT Transporter (ABCA7).";

RL Biochem. Biophys. Res. Commun. 273:532-538(2000).

DR EMBL: AF250238; AAF85794.1; -.
SQ SEQUENCE 2146 AA; 234468 MW; 679B16EB2D75FF0D CRC64;

Query Match 68.9%; Score 230; DB 4; Length 2146;

Best Local Similarity 67.8%; Pred. No. 2.3e-20;

Matches 40; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

OY 1 MACWPQLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 59

DB 1 MAFWTQLMLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 59

RESULT 5

Q35600

ID Q35600 PRELIMINARY; PRT; 2310 AA.

AC Q35600;

DT 01-JAN-1998 (TReMBLrel. 05, Created)

DT 01-JAN-1998 (TReMBLrel. 05, Last sequence update)

DT 01-OCT-2000 (TReMBLrel. 15, Last annotation update)

DE ATP-BINDING CASSETTE TRANSPORTER.

GN ABCA4 OR ABC10 OR ABCR.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6;

RX MEDLINE=97345663; PubMed=9202155;

RA Azarian S.M., Travis G.H.;

RT "The photoreceptor rim protein is an ABC transporter encoded by the

RT gene for recessive Stargardt's disease (ABCR).";

RL FEBS Lett. 409:247-252(1997).

DR EMBL: AF000149; AAC23916.1; -.
DR MGD: MGI:109424; Abca4.

DR INTERPRO: IPR001617; -.
DR PFAM: PF00005; ABC_tran; 2.

DR PROSITE: PS00211; ABC_TRANSPORTER; UNKNOWN_1.

KW ATP-binding.

SQ SEQUENCE 2310 AA; 260207 MW; 8370C6C8A62EF294 CRC64;

Query Match

Best Local Similarity 55.4%; Score 185; DB 11; Length 2310;

Matches 32; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

OY 6 QLRLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

DB 6 QIQLLLKKNLTFRRTQCOLLLEAVWPLFLILISVRLSYPPYEQHECHFPNKA 60

RESULT 6

O02698

ID O02698 PRELIMINARY; PRT; 2281 AA.

AC O02698;

DT 01-JUL-1997 (TReMBLrel. 04, Created)

DT 01-JUL-1997 (TReMBLrel. 04, Last sequence update)

DT 01-JUN-2000 (TReMBLrel. 14, Last annotation update)

DT	01-MAY-2000 (T=EMBLrel. 13, Last sequence update)
DT	01-JUN-2000 (T=EMBLrel. 14, Last annotation update)
DE	CGI718 PROTEIN.
OS	Drosophila melanogaster (Fruit fly).
GN	Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC	Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
CC	Ephydroidea; Drosophilidae; Drosophila.
OX	NCBI_TaxID=7227;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	SPRAIN-BERKELEY.
XC	MEDLINE=20196006; PubMed=107311132;
RA	Adams M.D., Celisner S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA	Ananides P.G., Scher S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA	George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA	Sutton G.G., Wortman J.R., Vandell M.D., Zhang Q., Chen L.X.,
RA	Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA	Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA	Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA	Ballev R.M., Basu A., Bakendale J.P., Bayraktaroglu L., Beasley E.M.,
RA	Beeon K.Y., Benos P.V., Bereman B.P., Bhandari D., Bolshakov S.,
RA	Borkova D., Botchan M.R., Bouck J., Brockstein P., Brottier P.,
RA	Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA	Cherry J.M., Crawley S., Dahlke C., Davenport L.B., Davies P.,
RA	de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA	Dodson K., Dou P.L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA	Dubin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA	Fosler C., Gabrieli A.E., Farr N.S., Gelbart W.M., Glasser K.,
RA	Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA	Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA	Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA	Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA	Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA	Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA	Liu X., Mattel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA	Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA	Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA	Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA	Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA	Reiner K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA	Shue B.C., Siden-Kianos I., Simpson M., Skupski M.P., Smith T.,
RA	Spirer E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA	Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA	wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissbach J.,
RA	Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA	Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA	Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu H.O.,
RA	Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.:
RT	"The genome sequence of Drosophila melanogaster."
RL	Science 287:2185-2195(2000).
DR	ENBL: AE003568; AAF50837.1; -
DR	FLYBASE: FBgn0031170; CGI718.
DR	INTERPRO: IPRO001617; -
DR	PFAM: PF00005; ABC_tran; 2.
DR	PROSITE: PS00211; ABC_TRANSPORTER; 1.
SQ	SEQUENCE 1713 AA; 192888 MW; 9DE2D3BF9B9DC1CA CRC64;

Query Match	23.4%;	Score 78;	DB 5;	Length 1713;
Best Local Similarity	37.5%;	Pred. No. 0.19;		
Matches 15;	Conservative	8;	Mismatches 17;	Indels 0; Gaps

QY	4 WPOLRLLLKWNLFRRROTCOLLELVAVPLIFLILISVR 43
	: : : : : : : :
Db	7 WDFVPLLKKNTQLQNNHKWKQMVIELVLPAIFSLLDLVR 46

RESULT	9
Q9T050	
ID	Q9T050 PRELIMINARY; PRT: 707 AA.
AC	Q9T050;
DT	01-MAY-2000 (T=EMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DE 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
 DE HYPOTHETICAL 79.4 KDA PROTEIN.
 GN T26M18.20 OR AT4G11810.
 OS Arabidopsis thaliana (Mouse-ear cress).
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
 OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
 OC Brassicales; Brassicaceae; Arabidopsids.
 OX NCBI_TaxID=3702;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bevan M., Hilbert H., Braun M., Holzer E., Brandt A., Duesterhoeft A.,
 RA Bancroft I., Mewes H.W., Mayer K.F.X., Lemcke K., Mannhaupt G.,
 RA Schueller C.;
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RA EU Arabidopsis sequencing project;
 RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RA Hilbert H., Braun M., Holzer E., Brandt A., Duesterhoeft A.,
 RA Mewes H.W., Lemcke K., Mayer K.F.X.;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RP SEQUENCE FROM N.A.
 RA EU Arabidopsis sequencing project;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AL078606; CAB44319.1; -;
 DR EMBL; AL161532; CAB78224.1; -;
 KW Hypothetical protein.
 SQ SEQUENCE 707 AA; 79418 MW; DA1F8F4BF88A7FF2 CRC64;

 Query Match 21.4%; Score 71.5; DB 10; Length 707;
 Best Local Similarity 36.7%; Pred. No. 0.56; 24; Indels 7; Gaps 2;
 Matches 22; Conservative 7; Mismatches 24; Indels 7; Gaps 2;

 QY 1 MACWPQLRLLLW-----KNLTFRRRTQCQLLEAVWPLFIFILISVRLSPYPPYEQHECH 55
 DB 390 MACGPALAGLLODFKIKNVTFNQDTLPGWMAVALLVLWLAISFR--EPAREPEIH 447

 RESULT 10
 Q9PVM2 PRELIMINARY; PRT; 307 AA.
 AC Q9PVM2;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created).
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DE 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE OLFACTORY RECEPTOR 1.
 GN MF0R1.
 OS Oryzias latipes (Medaka fish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziinae; Oryzias.
 OX NCBI_TaxID=8090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-NGY;
 RA Sun H., Kondo R., Shima A., Naruse K., Hori H., Chigusa S.I.;
 RT "Evolutionary analysis of putative olfactory receptor genes of medaka
 fish, Oryzias latipes.";
 RL Gene 231:137-145(1999).
 DR EMBL; AB022646; BAA84275.1; -;
 DR INTERPRO; IPR000276; -;
 DR PFAM; PF00001; 7tm_1; 1.
 DR PRINTS; PR00237; GPCRHHODPSN.
 DR PROSITE; PS00237; G_PROTEIN_RECEPTOR; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 307 AA; 35400 MW; E14065B68FCCBEF8 CRC64;

 Query Match 21.4%; Score 71.5; DB 10; Length 707;
 Best Local Similarity 36.7%; Pred. No. 0.56; 24; Indels 7; Gaps 2;
 Matches 22; Conservative 7; Mismatches 24; Indels 7; Gaps 2;

 QY 1 MACWPQLRLLLW-----KNLTFRRRTQCQLLEAVWPLFIFILISVRLSPYPPYEQHECH 55
 DB 390 MACGPALAGLLODFKIKNVTFNQDTLPGWMAVALLVLWLAISFR--EPAREPEIH 447

 RESULT 10
 Q9PVM2 PRELIMINARY; PRT; 307 AA.
 AC Q9PVM2;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created).
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DE 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE OLFACTORY RECEPTOR 1.
 GN MF0R1.
 OS Oryzias latipes (Medaka fish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziinae; Oryzias.
 OX NCBI_TaxID=8090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-NGY;
 RA Sun H., Kondo R., Shima A., Naruse K., Hori H., Chigusa S.I.;
 RT "Evolutionary analysis of putative olfactory receptor genes of medaka
 fish, Oryzias latipes.";
 RL Gene 231:137-145(1999).
 DR EMBL; AB022646; BAA84275.1; -;
 DR INTERPRO; IPR000276; -;
 DR PFAM; PF00001; 7tm_1; 1.
 DR PRINTS; PR00237; GPCRHHODPSN.
 DR PROSITE; PS00237; G_PROTEIN_RECEPTOR; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 307 AA; 35400 MW; E14065B68FCCBEF8 CRC64;

Query Match 19.6%; Score 65.5; DB 13; Length 307;
 Best Local Similarity 33.3%; Pred. No. 1.5;
 Matches 18; Conservative 8; Mismatches 21; Indels 7; Gaps 2;

 QY 3 CWPQLRLLLWKNLTFRRRTQCQLLEAVWPLFIFILISVRLSPYPPYEQHECHF 56
 DB 125 CKP-----LQYOSLSKRRVTWMLLSLWLPFLQLTVAISGKVI---INORPCSF 171

 RESULT 11
 Q9PVM1 PRELIMINARY; PRT; 307 AA.
 AC Q9PVM1;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE OLFACTORY RECEPTOR 2.
 GN MF0R2.
 OS Oryzias latipes (Medaka fish).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
 OC Belontiiformes; Adrianichthyidae; Oryziinae; Oryzias.
 OX NCBI_TaxID=8090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-NGY;
 RA Sun H., Kondo R., Shima A., Naruse K., Hori H., Chigusa S.I.;
 RT "Evolutionary analysis of putative olfactory receptor genes of medaka
 fish, Oryzias latipes.";
 RL Gene 231:137-145(1999).
 DR EMBL; AB022647; BAA84276.1; -;
 DR INTERPRO; IPR000276; -;
 DR PFAM; PF00001; 7tm_1; 1.
 DR PRINTS; PR00237; GPCRHHODPSN.
 DR PROSITE; PS00237; G_PROTEIN_RECEPTOR; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 307 AA; 35678 MW; BCA9C5FDF050B7D8 CRC64;

 Query Match 19.6%; Score 65.5; DB 13; Length 307;
 Best Local Similarity 33.3%; Pred. No. 1.5;
 Matches 18; Conservative 8; Mismatches 21; Indels 7; Gaps 2;

 QY 3 CWPQLRLLLWKNLTFRRRTQCQLLEAVWPLFIFILISVRLSPYPPYEQHECHF 56
 DB 125 CKP-----LQYOSLSKRRVTWMLLSLWLPFLQLTVAISGKVI---INORPCSF 171

 RESULT 12
 Q9ZPB9 PRELIMINARY; PRT; 129 AA.
 AC Q9ZPB9;
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
 DE MATURASE (FRAGMENT).
 GN YCF14 OR MATK.
 OS Crawfordia speciosa.
 OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
 OC Magnoliophyta; eudicotyledons; core eudicots; Asteridae; euasterids I;
 OC Gentianales; Gentianaceae; Crawfordia.
 OX NCBI_TaxID=82711;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Thiv M., Kadereit J.W.;
 RT "The phylogenetic relationships and evolution of the Canarian laurel
 forest endemic Ixanthus viscosus (Ait.) Griseb. (Gentianaceae):
 evidence from matk and ITS sequences.";
 RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ010512; CAB37008.1; -;
 DR MENDEL; 40044; Crasp; ycf14; 40044.

```

RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.:
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
DR EMBL; AE003477; AAF47740.1; -.
DR FLYBASE; FBgn0035420; CG14967.
SQ SEQUENCE 2272 AA; 259619 MW; 4102D7EC483A3298 CRC64;

Query Match      18.4%; Score 61.5; DB 5; Length 2272;
Best Local Similarity 27.5%; Pred. No. 28;
Matches 22; Conservative 9; Mismatches 26; Indels 23; Gaps

QY 2 ACWPQLRLLWKNLFRRTQCQL-----LEVAMP-----LFIFLI 38
   ||| ||||| || : || : |
Db 1142 ACWEPLRLLHGRULTIAKQFTILLHASLDPYNTTEEMELTWNCIGVLTNAKINFKGEL 120
   ||| ||||| || : || : |

QY 39 LISVRLSPYPPEQHECHFPN 58
   ::|| : : ||||
Db 1202 NVTVRTASRYDDCRLHFNP 1221

RESULT 14
Q9NF52 PRELIMINARY; PRT; 218 AA.
ID C9NF52;
AC Q9NF52;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DE BACNSI9.GS.1.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephyrdoidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA Murphy L., Harris D., Barrell B.;
RT "Sequencing the distal X chromosome of Drosophila melanogaster.";
RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Benos P.;
RT Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RL EMBL; AL121800; CAB58006.1; -.
SQ SEQUENCE 218 AA; 25502 MW; E9DF6B80F0356CBA CRC64;

Query Match      18.3%; Score 61; DB 5; Length 218;
Best Local Similarity 23.3%; Pred. No. 4;
Matches 14; Conservative 17; Mismatches 27; Indels 2; Gaps

QY 1 MACWPQLRLLWKNLFRRTQCQL-LLEVAWPLFF-LILISVRLSPYPPEQHECHFPN 58
   :| | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 90 LAWMQRHFVYLKHWTLRKARLLSLAILTAWLMILIYGIVTDLP LRHVAMDSGGQHRPN 149
   :| | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 15
O82747 PRELIMINARY; PRT; 598 AA.
ID O82747;
AC O82747;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DE HYPOTHETICAL 67.7 KDA PROTEIN.
GN FTH19.170 OR AT4G22990.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
OC Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
OC Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Peters S.A., van Staveren M., Dirkse W., Stiekema W., Bancroft I.
```

Query Match 18.1%; Score 60.5; DB 10; Length 598;
Best Local Similarity 30.5%; Pred. No. 11;
Matches 18; Conservative 11; Mismatches 21; Indels 9; Gaps 3;

Search completed: May 31, 2001, 13:09:59
Job time: 325 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 13:03:59 ; Search time 31.1 Seconds
(without alignments)
66.088 Million cell updates/sec.

Title: US-09-526-193a-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLKLNKLTERR.....SVRLSYPPYRQHCHECFNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 93435 seqs, 34255486 residues

Total number of hits satisfying chosen parameters: 93435

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_39:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	334	100.0	2261	1 ABC1_HUMAN	O95477 homo sapien
2	334	100.0	2261	1 ABC1_MOUSE	P41233 mus musculus
3	180	53.9	2273	1 ABC3_HUMAN	P78363 homo sapien
4	84	25.1	1704	1 ABC3_HUMAN	O99758 homo sapien
5	65.5	19.6	778	1 FTSK_COXBU	P39920 coxiella bu
6	60.5	18.1	511	1 ACH5_CAEEL	Q23022 caenorhabdi
7	58.5	17.5	383	1 F062_SOYBN	P48631 glycine max
8	57	17.1	1093	1 SYV_NEUCR	P28350 neurospora
9	57	17.1	1103	1 CYGF_BOVIN	O02740 bos taurus
10	56.5	16.9	870	1 Y563_HUMAN	O60309 homo sapien
11	56	16.8	463	1 DSDR_FUGRU	P53454 fugu rubrip
12	56	16.8	921	1 CR2A_BOVIN	P14099 bos taurus
13	56	16.8	941	1 CR2A_HUMAN	O00408 homo sapien
14	55.5	16.6	436	1 ACHX_ONCVO	P54247 onchocerca
15	55.5	16.6	837	1 AT54_HUMAN	O75173 homo sapien
16	55	16.5	357	1 YCF4_ECOLI	P75955 escherichia
17	55	16.5	383	1 F06E_ARATH	P46313 arabidopsis
18	55	16.5	928	1 CR2A_RAT	O01062 rattus norv
19	54	16.2	2005	1 CIN2_HUMAN	Q99250 homo sapien
20	54	16.2	2005	1 CIN2_RAT	P04775 rattus norv
21	53.5	16.0	333	1 CXCL_HUMAN	P46094 homo sapien
22	53.5	16.0	1682	1 CIN6_HUMAN	O01118 homo sapien
23	53	15.9	475	1 DMR_MENPI	Q98503 mentha pipe
24	53	15.9	638	1 NTGL_BOVIN	P02830 bos taurus
25	53	15.9	1229	1 F443_TRYBB	Q99280 trypanosoma
26	52.5	15.7	282	1 NU2M_CAEEL	P24889 caenorhabdi
27	52.5	15.7	345	1 PSR_CAVPO	O70129 cavia porce
28	52.5	15.7	434	1 FSR_ERWCH	O53900 erwinnia chr
29	52.5	15.7	465	1 DDDR_XENLA	P42291 xenopus lae
30	52.5	15.7	676	1 EX1L_HUMAN	Q92935 homo sapien
31	52	15.6	378	1 EXT1_CAEEL	O01704 caenorhabdi
32	52	15.6	633	1 NTGL_MOUSE	P28571 mus musculus
33	52	15.6	633	1 NTGL_RAT	P28572 rattus norv

RESULT 1

ID	ABC1_HUMAN	STANDARD:	PRT: 2261 AA.
AC	O95477: Q9UN08; Q9UN07: Q9UN06; Q9NQV4; Q9UN09;		
DT	01-OCT-2000 (Rel. 40, Created)		
DT	01-OCT-2000 (Rel. 40, Last sequence update)		
DE	ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 1 (ATP-BINDING CASSETTE		
DE	TRANSPORTER 1) (ATP-BINDING CASSETTE 1) (ABC-1) (CHOLESTEROL EFFLUX		
DE	REGULATORY PROTEIN).		
GN	ABCA1 OR ABC1 OR CERP.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RX	SEQUENCE FROM N.A.		
RX	MEDLINE=20345099; PubMed=10884428;		
RA	Santamarina-Fojo S., Peterson K.M., Knapper C.L., Qiu Y.,		
RA	Freeman L.A., Cheng J.-F., Osorio J., Remaley A.T., Yang X.-P.,		
RA	Haudenschild C.C., Prades C., Chimini G., Blackmon E.E.,		
RA	Francois T.L., Duverger N., Rubin E.M., Rosier M., Deneffe P.,		
RA	Fredrickson D.S., Brewer H.B. Jr.;		
RT	"Complete genomic sequence of the human ABCA1 gene: analysis of the		
RT	human and mouse ATP-binding cassette A promoter.";		
RL	Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).		
RN	[2]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=Skin;		
RA	Schwartz K., Lawn R.M., Wade D.P.;		
RT	"ABCA1 gene expression and apoA-I-mediated cholesterol efflux are		
RT	regulated by LXR.";		
RL	Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.		
RN	[3]		
RP	SEQUENCE OF 21-2261 FROM N.A.		
RX	PubMed=10092505;		
RA	Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F.,		
RA	Chimini G., Kaminski W., Schmitz G.;		
RT	"Molecular cloning of the human ATP-binding cassette transporter 1		
RT	(hABC1): evidence for dimeric regulation in macrophages.";		
RL	Biochem. Biophys. Res. Commun. 257:29-33(1999).		
RN	[4]		
RP	SEQUENCE OF 21-2261 FROM N.A.		
RX	MEDLINE=99364413; PubMed=10431238;		
RA	Rust S., Rosier M., Funke H., Real J., Amoura Z., Plette J.-C.,		
RA	Deleuze J.-F., Brewer H.B., Duverger N., Deneffe P., Assmann G.;		
RT	"Tangier disease is caused by mutations in the gene encoding		
RT	ATP-binding cassette transporter 1.";		
RL	Nat. Genet. 22:352-355(1999).		
RN	[5]		
RP	VARIANTS TD ARG-597; LEU-693 DEL AND ARG-1477.		
RX	MEDLINE=99364411; PubMed=10431236;		
RA	Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.-H., Roomp K.,		
RA	van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F.,		
RA	Loubser O., Ouellette B.F.F., Fichter K., Ashbourne-Excoffon K.J.,		
RA	Sensen C.W., Scherer S., Mott S., Denis M., Martindale D.,		

P48067 homo sapien
Q9nv46 homo sapien
P08104 rattus norv
Q14524 homo sapien
P15389 rattus norv
Q10045 caenorhabdi
Q9r0m1 mus musculu
Q99500 homo sapien
P46071 porphyromon
P35498 homo sapien
P04774 rattus norv
Q02458 proteus mir

ALIGNMENTS

RA Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.,
Hayden M.R.;
RT "Mutations in ABC1 in Tangier disease and familial high-density
RT lipoprotein deficiency.";
RL Nat. Genet. 22:336-345(1999).
[6]
RN VARIANTS TD SER-590; SER-935 AND VAL-937.
RX MEDLINE-99364412; PubMed-10431237;
RA Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A.,
RA Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Oczurumez M.,
RA Kaminski W.E., Hammann H.W., Oette K., Rothe G., Aslanidis C.,
RA Lackner K.J., Schmitz G.;
RT "The gene encoding Arg-binding cassette transporter 1 is mutated in
RT Tangier disease.";
RL Nat. Genet. 22:347-351(1999).
[7]
RN VARIANTS TD LEU-1289 AND HIS-1800.
RX MEDLINE-20171564; PubMed-10706591;
RA Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA Van Berdwegh P., Goldkamp A.L., Thurston L.M., FitzGerald M.G.,
RA Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA Ordovas J.M., Freeman M.W., Brown R.H. Jr., Gu J.Z.;
RT "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT tangier disease kindreds.";
RL J. Lipid Res. 41:433-441(2000).
CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
CC TRANSPORT.
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED, BUT MOST ABUNDANT IN
CC MACROPHAGES.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN.
CC -1- DISEASE: DEFECTS IN ABCA1 ARE A CAUSE OF TANGIER DISEASE (TD). TD
CC IS A RECESSIVE DISORDER CHARACTERIZED BY ABSENCE OF HIGH DENSITY
CC LIPOPROTEIN (HDL) CHOLESTEROL FROM PLASMA, HEPATOSPLENOMEGALY,
CC PERIPHERAL NEUROPATHY, AND FREQUENTLY PREMATURE CORONARY ARTERY
CC DISEASE (CHD).
CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS). MDR SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF275948; AAF86276.1; -;
DR EMBL; AF285167; AAF98175.1; -;
DR EMBL; AJ012376; CAA10005.1; ALT_INIT.
DR EMBL; AF165281; AAD49849.1; ALT_INIT.
DR EMBL; AF165286; AAD49851.1; -;
DR EMBL; AF165282; AAD49851.1; JOINED.
DR EMBL; AF165283; AAD49851.1; JOINED.
DR EMBL; AF165284; AAD49851.1; JOINED.
DR EMBL; AF165285; AAD49851.1; JOINED.
DR EMBL; AF165306; AAD49852.1; -;
DR EMBL; AF165287; AAD49852.1; JOINED.
DR EMBL; AF165288; AAD49852.1; JOINED.
DR EMBL; AF165289; AAD49852.1; JOINED.
DR EMBL; AF165290; AAD49852.1; JOINED.
DR EMBL; AF165291; AAD49852.1; JOINED.
DR EMBL; AF165292; AAD49852.1; JOINED.
DR EMBL; AF165293; AAD49852.1; JOINED.
DR EMBL; AF165294; AAD49852.1; JOINED.
DR EMBL; AF165295; AAD49852.1; JOINED.
DR EMBL; AF165296; AAD49852.1; JOINED.
DR EMBL; AF165297; AAD49852.1; JOINED.
DR EMBL; AF165298; AAD49852.1; JOINED.
DR EMBL; AF165299; AAD49852.1; JOINED.
DR EMBL; AF165300; AAD49852.1; JOINED.

DR EMBL; AF165301; AAD49852.1; JOINED.
DR EMBL; AF165302; AAD49852.1; JOINED.
DR EMBL; AF165303; AAD49852.1; JOINED.
DR EMBL; AF165304; AAD49852.1; JOINED.
DR EMBL; AF165305; AAD49852.1; JOINED.
DR EMBL; AF165306; AAD49852.1; JOINED.
DR EMBL; AF165307; AAD49854.1; -;
DR EMBL; AF165307; AAD49854.1; JOINED.
DR EMBL; AF165308; AAD49854.1; JOINED.
DR EMBL; AF165310; AAD49853.1; -;
DR MIM; 600046; -;
DR MIM; 205400; -;
DR InterPro; IPR001617; -;
DR Pfam; PF00005; ABC_tran; 2.
KW PROSITE; PS0211; ABC_TRANSPORTER; 1.
KW ATP-binding; Glycoprotein; Transmembrane; Transport;
KW Disease mutation.
FT TRANSMEM 26 42 POTENTIAL.
FT TRANSMEM 640 656 POTENTIAL.
FT TRANSMEM 690 706 POTENTIAL.
FT TRANSMEM 717 733 POTENTIAL.
FT TRANSMEM 749 765 POTENTIAL.
FT TRANSMEM 771 787 POTENTIAL.
FT TRANSMEM 1041 1057 POTENTIAL.
FT TRANSMEM 1351 1367 POTENTIAL.
FT TRANSMEM 1661 1677 POTENTIAL.
FT TRANSMEM 1708 1724 POTENTIAL.
FT TRANSMEM 1737 1753 POTENTIAL.
FT TRANSMEM 1775 1791 POTENTIAL.
FT TRANSMEM 1854 1870 POTENTIAL.
FT NP_BIND 933 940 ATP (POTENTIAL).
FT NP_BIND 1946 1953 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 98 98 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 151 151 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 161 161 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 196 196 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 244 244 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 292 292 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 337 337 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 349 349 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 400 400 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 478 478 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 489 489 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 521 521 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 820 820 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1144 1144 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1294 1294 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1453 1453 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1504 1504 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1637 1637 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2044 2044 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2238 2238 N-LINKED (GLCNAC. .) (POTENTIAL).
FT VARIANT 399 399 V -> A (IN TD).
FT VARIANT 587 587 /FTid=VAR_009145.
FT VARIANT 590 590 R -> W (IN TD).
FT VARIANT 590 590 /FTid=VAR_009146.
FT VARIANT 597 597 W -> S (IN TD).
FT VARIANT 597 597 /FTid=VAR_009147.
FT VARIANT 693 693 O -> R (IN TD).
FT VARIANT 935 935 /FTid=VAR_009148.
FT VARIANT 937 937 MISSING (IN TD).
FT VARIANT 1289 1289 /FTid=VAR_009149.
FT VARIANT 1477 1477 N -> S (IN TD).
FT VARIANT 1517 1517 /FTid=VAR_009150.
FT VARIANT 1800 1800 A -> V (IN TD).
FT VARIANT 1800 1800 /FTid=VAR_009151.
FT VARIANT 1800 1800 D -> L (IN TD).
FT VARIANT 1800 1800 /FTid=VAR_009152.
FT VARIANT 1800 1800 C -> R (IN TD).
FT VARIANT 1800 1800 /FTid=VAR_009153.
FT VARIANT 1800 1800 I -> R (IN TD).
FT VARIANT 1800 1800 /FTid=VAR_009154.
FT VARIANT 1800 1800 N -> H (IN TD).

Query Match 100.0%; Score 334; DB 1; Length 2261;
Best Local Similarity 100.0%; Pred. No. 1.4e-31;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKNTFRRTQTCOLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLKNTFRRTQTCOLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60

RESULT 2

ID ABC1_MOUSE STANDARD; PRT: 2261 AA.
AC P41233;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-OCT-2000 (Rel. 40, Last sequence update)
DE ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 1 (ATP-BINDING CASSETTE
DE TRANSPORTER 1) (ATP-BINDING CASSETTE 1) (ABC-1).
GN ABCA1 OR ABC1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
RC STRAIN-DBA/2; TISSUE-Macrophage;
RX MEDLINE=94375008; PubMed=8088782;
RA Luciani M.F., Denizot F., Savary S., Mattei M.-G., Chimini G.;
RT "Cloning of two novel ABC transporters mapping on human chromosome
9.";
RL Genomics 21:150-159(1994).
RN [2]

SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J;
RA Qiu Y., Cavellier L., Chiu S., Rubin E., Cheng J.-F.;
RT "Human and mouse ABCA1 comparative sequencing and transgenesis studies
Identify potential regulatory sequences.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
CC TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
CC TRANSPORT (BY SIMILARITY).
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST
CC LEVELS ARE FOUND IN PREGNANT UTERUS AND UTERUS.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN.
CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS). MDR SUBFAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----

DR EMBL; X75926; CAA53530.1; ALT_INIT.

DR EMBL; AF287263; AAC39073.1; ALT_INIT.

DR MGB; MGI:99607; Abca1.

DR InterPro; IPR001617; .

DR Pfam; PF00005; ABC_tran; 2.

DR PROSITE; PS00211; ABC_TRANSPORTER; 1.

KW ATP-binding; Glycoprotein; Transmembrane; Transport.

FT TRANSMEM 26 42 POTENTIAL.

FT TRANSMEM 640 656 POTENTIAL.

FT TRANSMEM 690 706 POTENTIAL.

FT TRANSMEM 717 733 POTENTIAL.

FT TRANSMEM 749 765 POTENTIAL.

FT TRANSMEM 771 787 POTENTIAL.

FT TRANSMEM 1041 1057 POTENTIAL.

FT TRANSMEM 1351 1367 POTENTIAL.

FT TRANSMEM 1661 1677 POTENTIAL.
FT TRANSMEM 1708 1724 POTENTIAL.
FT TRANSMEM 1737 1753 POTENTIAL.
FT TRANSMEM 1775 1791 POTENTIAL.
FT TRANSMEM 1854 1870 POTENTIAL.
FT NP_BIND 933 940 ATP (POTENTIAL).
FT NP_BIND 1946 1953 ATP (POTENTIAL).
FT CARBOHYD 14 14 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 98 98 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 151 151 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 161 161 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 196 196 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 244 244 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 292 292 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 337 337 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 349 349 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 400 400 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 478 478 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 489 489 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 521 521 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 820 820 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1144 1144 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1294 1294 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1453 1453 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1499 1499 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1504 1504 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 1637 1637 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2044 2044 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 2238 2238 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CONFLICT 1567 1568 MISSING (IN REF. 2).
FT CONFLICT 2024 2024 MISSING (IN REF. 2).
SQ SEQUENCE 2261 AA; 254011 MW; FAE62B21FD1D09F9 CRC64;

Query Match 100.0%; Score 334; DB 1; Length 2261;
Best Local Similarity 100.0%; Pred. No. 1.4e-31;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACWPQLRLLLKNTFRRTQTCOLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 MACWPQLRLLLKNTFRRTQTCOLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60

RESULT 3

ABCR_HUMAN

ID ABCR_HUMAN STANDARD; PRT: 2273 AA.
AC P78363; O60438; O60915; O15112;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 01-OCT-2000 (Rel. 40, Last annotation update)
DE RETINAL-SPECIFIC ATP-BINDING CASSETTE TRANSPORTER (RIM ABC
DE TRANSPORTER) (RIM PROTEIN) (RMP) (STARGARDT DISEASE PROTEIN).
GN ABCA4 OR ABCR.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. AND VARIANTS STGD.
RX MEDLINE=97207641; PubMed=9054934;
RA Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A.,
RA Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A.,
RA Rattner A., Smallwood P., Li Y., Anderson K.L., Lewis R.A.,
RA Nathans J., Leppert M., Dean M., Lupski J.R.;
RT "A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is
RT mutated in recessive Stargardt macular dystrophy.";
RL Nat. Genet. 15:236-246(1997).
RN [2]

SEQUENCE FROM N.A.

RN MEDLINE=97345663; PubMed=9202155;

RX Azarian S.M., Travis G.H.;

RT "The photoreceptor rim protein is an ABC transporter encoded by the
RT gene for recessive Stargardt's disease (ABCR).";

RL FEBS Lett. 409:247-252(1997).
RN [3]
RP SEQUENCE FROM N.A., AND VARIANTS STGD W-18 AND C-212.
RX MEDLINE-98163759; PubMed-9503029;
RA Gerber S., Rozet J.M., van de Pol T.J.R., Hoying C.B., Munnich A.,
RA Blankenagel A., Kaplan J., Cremers F.P.M.;
RT "Complete exon-intron structure of the retina-specific ATP binding
RT transporter gene (ABCR) allows the identification of novel mutations
RL underlying Stargardt disease.";
RL Genomics 48:139-142(1998).
RN [4]
RP SEQUENCE FROM N.A., AND VARIANTS STGD.
RX MEDLINE-98141133; PubMed-9490294;
RA Nasonkin I., Illing M., Koehler M.R., Schmid M., Molday R.S.,
RA Weber B.H.;
RT "Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1
RT and identification of novel mutations in Stargardt's disease.";
RL Hum. Genet. 102:21-26(1998).
RN [5]
RP CHARACTERIZATION.
RX MEDLINE-99175213; PubMed-10075733;
RA Sun H., Molday R.S., Nathans J.;
RT "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR,
RT the photoreceptor-specific ATP-binding cassette transporter
RT responsible for Stargardt disease.";
RL J. Biol. Chem. 274:8269-8281(1999).
RN [6]
RP VARIANTS ARMD2.
RX MEDLINE-97442530; PubMed-9295268;
RA Allikmets R., Shroyer N.F., Singh N., Seddon J.M., Lewis R.A.,
RA Bernstein P.S., Peliffer A., Zabriskie N.A., Li Y., Hutchinson A.,
RA Dean M., Lupski J.R., Leppert M.;
RT "Mutation of the Stargardt disease gene (ABCR) in age-related macular
RT degeneration.";
RL Science 277:1805-1807(1997).
RN [7]
RP VARIANTS STGD.
RX MEDLINE-98454319; PubMed-9781034;
RA Rozet J.M., Gerber S., Souied E., Perrault I., Chatelin S., Ghazi I.,
RA Leowski C., Dufier J.L., Munnich A., Kaplan J.;
RT "Spectrum of ABCR gene mutations in autosomal recessive macular
RT dystrophies.";
RL Eur. J. Hum. Genet. 6:291-295(1998).
RN [8]
RP VARIANTS STGD.
RX MEDLINE-99138655; PubMed-9973280;
RA Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A.,
RA Li Y., Lupski J.R., Leppert M., Dean M.;
RT "Genotype/phenotype analysis of a photoreceptor-specific ATP-binding
RT cassette transporter gene, ABCR, in Stargardt disease.";
RL Am. J. Hum. Genet. 64:422-434(1999).
RN [9]
RP VARIANTS STGD, AND VARIANTS.
RX MEDLINE-99192348; PubMed-10090887;
RA Maugeri A., van Driel M.A., van de Pol D.J.R., Klevering B.J.,
RA van Haren F.J., Tijmes N., Bergen A.B., Rohrschneider K.,
RA Blankenagel A., Pinckers A.J.L.G., Dahl N., Brunner H.G.,
RA Deutman A.F., Hoying C.B., Cremers F.P.M.;
RT "The 2588G-->C mutation in the ABCR gene is a mild frequent founder
RT mutation in the western European population and allows the
RT classification of ABCR Mutations in patients with Stargardt disease.";
RL Am. J. Hum. Genet. 64:1024-1035(1999).
RN [10]
RP VARIANT STGD TYR-54, AND VARIANT ALA-863.
RX MEDLINE-20077755; PubMed-10612508;
RA Zhang K., Garibaldi D.C., Kliazeva M., Albini T., Chiang M.F.,
RA Kerrigan M., Sunness J.S., Han M., Allikmets R.;
RT "A novel mutation in the ABCR gene in four patients with autosomal
RT recessive Stargardt disease.";
RL Am. J. Ophthalmol. 128:720-724(1999).
RN [11]
RP VARIANTS STGD.
RX MEDLINE-20098082; PubMed-10634594;
RA Papaiannou M., Oaka L., Bessant D., Lois N., Bird A., Payne A.,
RA Bhattacharya S.;
RT "An analysis of ABCR mutations in British patients with recessive
RT retinal dystrophies.";
RL Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
RN [12]
RP FUNCTION: MAY PLAY A ROLE IN PHOTORESPONSE. RETINOIDS, AND MOST
CC LIKELY RETINAL, ARE THE NATURAL SUBSTRATES FOR TRANSPORT BY ABCR
CC IN ROD OUTER SEGMENTS. MAY ACT IN THE VISUAL CYCLE TO FLIP PE-ALL-
CC TRANS-RETINAL ADDUCTS FROM THE LUMENAL TO THE CYTOSOLIC FACE OF
CC THE DISC MEMBRANE, MOVE FREE ALL-TRANS-RETINAL FROM THE LIPID
CC PHASE OF THE DISC MEMBRANE TO A JUXTAMEMBRANE LOCATION, OR
CC POSSIBLY REORIENT ALL-TRANS-RETINAL IN THE BILAYER.
CC SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.
CC TISSUE SPECIFICITY: RETINAL-SPECIFIC. SEEMS TO BE EXCLUSIVELY
CC FOUND IN THE RIMS OF ROD PHOTORECEPTOR CELLS.
CC DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF STARGARDT DISEASE (STGD);
CC ALSO KNOWN AS FUNDUS FLAVIMACULATUS (FFM) OR JUVENILE MACULAR
CC DEGENERATION. IT IS AN AUTOSOMAL RECESSIVE RETINAL DISORDER. IT IS
CC ONE OF THE MOST FREQUENT CAUSES OF MACULAR DEGENERATION IN
CC CHILDHOOD. IT IS CHARACTERIZED BY A JUVENILE-ONSET MACULAR
CC DYSTROPHY, ALTERATIONS OF THE PERIPHERAL RETINA, AND SUBRETINAL
CC DEPOSITION OF LIPOFUSCIN-LIKE MATERIAL.
CC DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF AGE-RELATED MACULAR
CC DEGENERATION (ARMD2 OR AMD).
CC DISEASE: DEFECTS IN ABCA4 ARE A CAUSE OF AUTOSOMAL RECESSIVE CONE-
CC ROD DYSTROPHY (ARCRD OR CRD).
CC SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS).
CC DATABASE: NAME-Mutations of the ABCA4 gene;
CC NOTE-Retina International's Scientific Newsletter;
CC WWW="http://www.irpa.org/sci-news/abcrmut.htm".

CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL; U88667; AAC51144.1;
DR EMBL; AF000148; AAC23915.1;
DR EMBL; Y15635; CAA75729.1; JOINED.
DR EMBL; Y15636; CAA75729.1; JOINED.
DR EMBL; Y15637; CAA75729.1; JOINED.
DR EMBL; Y15638; CAA75729.1; JOINED.
DR EMBL; Y15639; CAA75729.1; JOINED.
DR EMBL; Y15640; CAA75729.1; JOINED.
DR EMBL; Y15641; CAA75729.1; JOINED.
DR EMBL; Y15642; CAA75729.1; JOINED.
DR EMBL; Y15643; CAA75729.1; JOINED.
DR EMBL; Y15644; CAA75729.1; JOINED.
DR EMBL; Y15645; CAA75729.1; JOINED.
DR EMBL; Y15646; CAA75729.1; JOINED.
DR EMBL; Y15647; CAA75729.1; JOINED.
DR EMBL; Y15648; CAA75729.1; JOINED.
DR EMBL; Y15649; CAA75729.1; JOINED.
DR EMBL; Y15650; CAA75729.1; JOINED.
DR EMBL; Y15651; CAA75729.1; JOINED.
DR EMBL; Y15652; CAA75729.1; JOINED.
DR EMBL; Y15653; CAA75729.1; JOINED.
DR EMBL; Y15654; CAA75729.1; JOINED.
DR EMBL; Y15655; CAA75729.1; JOINED.
DR EMBL; Y15656; CAA75729.1; JOINED.
DR EMBL; Y15657; CAA75729.1; JOINED.
DR EMBL; Y15658; CAA75729.1; JOINED.
DR EMBL; Y15659; CAA75729.1; JOINED.
DR EMBL; Y15660; CAA75729.1; JOINED.
DR EMBL; Y15661; CAA75729.1; JOINED.
DR EMBL; Y15662; CAA75729.1; JOINED.
DR EMBL; Y15663; CAA75729.1; JOINED.
DR EMBL; Y15664; CAA75729.1; JOINED.
DR EMBL; Y15665; CAA75729.1; JOINED.

DR EMBL; Y15666; CAA75729.1; JOINED.
DR EMBL; Y15667; CAA75729.1; JOINED.
DR EMBL; Y15668; CAA75729.1; JOINED.
DR EMBL; Y15669; CAA75729.1; JOINED.
DR EMBL; Y15670; CAA75729.1; JOINED.
DR EMBL; Y15671; CAA75729.1; JOINED.
DR EMBL; Y15672; CAA75729.1; JOINED.
DR EMBL; Y15673; CAA75729.1; JOINED.
DR EMBL; Y15674; CAA75729.1; JOINED.
DR EMBL; Y15675; CAA75729.1; JOINED.
DR EMBL; Y15676; CAA75729.1; JOINED.
DR EMBL; Y15677; CAA75729.1; JOINED.
DR EMBL; Y15678; CAA75729.1; JOINED.
DR EMBL; Y15679; CAA75729.1; JOINED.
DR EMBL; Y15680; CAA75729.1; JOINED.
DR EMBL; Y15681; CAA75729.1; JOINED.
DR EMBL; Y15682; CAA75729.1; JOINED.
DR EMBL; Y15683; CAA75729.1; JOINED.
DR EMBL; Y15684; CAA75729.1; JOINED.
DR EMBL; AF001945; AAC05632.1; -.
DR MIM; 601691; -.
DR MIM; 248200; -.
DR MIM; 153800; -.
DR InterPro; IPR001617; -.
DR Pfam; PF00005; ABC_tran; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.

Query Match 53.9%; Score 180; DB 1; Length 2273;
Best Local Similarity 56.4%; Pred. No. 1.8e-13;
Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

Oy 6 QLRLLLNKLTFRRTQCLLEVAWPLFLLISVRLSYPEYQHECHFPNKA 60
Db 6 QQLLWLNKWTURKQKRFVVELVWPLSLFLVLWLRNANPLYSHECHFPNKA 60

RESULT 4
ABC3_HUMAN STANDARD; PRT; 1704 AA.
ID ABC3_HUMAN STANDARD; PRT; 1704 AA.
AC Q99758; Q92473;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 3 (ATP-BINDING CASSETTE
DE TRANSPORTER 3) (ATP-BINDING CASSETTE 3) (ABC-C TRANSPORTER).
GN ABC3 OR ABC3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Thyroid carcinoma;
RX MEDLINE=96326608; PubMed=8706931;
RA Klugbauer N., Hofmann F.;
RT "Primary structure of a novel ABC transporter with a chromosomal
RT localization on the band encoding the multidrug resistance-associated
RT protein.";
RL FEBS Lett. 391:61-65(1996).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=97179225; PubMed=9027511;
RA Connors T.D., van Raay T.J., Petry L.R., Klinger K.W., Landes G.M.,
RA Burn T.C.;
RT "The cloning of a human ABC gene (ABC3) mapping to chromosome
RT 16p13.3.";
RL Genomics 39:231-234(1997).
CC -1- FOUND YET (MAY BE A TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN
CC IDENTIFIED (BY SIMILARITY). MAY ACT AS AN EFFLUX PUMP FOR
CC CHEMOTHERAPEUTICS DRUGS.
CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN LUNG, FOLLOWED BY BRAIN,
CC PANCREAS, SKELETAL MUSCLE AND HEART. WEAKLY EXPRESSED IN PLACENTA,
CC KIDNEY AND LIVER. ALSO EXPRESSED IN MEDULLARY THYROID CARCINOMA

CC CELLS (MTC) AND IN C-CELL CARCINOMA.
CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
CC EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
CC ATP BINDING CASSETTE (ABC) DOMAIN (BY SIMILARITY).
CC -1- SIMILARITY: BELONGS TO THE ATP-BINDING TRANSPORT PROTEIN FAMILY
CC (ABC TRANSPORTERS). MDR SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U78735; AAC50967.1; -.
DR EMBL; X97187; CAA05825.1; -.
DR MIM; 601615; -.
DR InterPro; IPR001617; -.
DR Pfam; PF00005; ABC_tran; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER; 1.
KW ATP-binding; transport; transmembrane.
FT TRANSMEM 22 42 POTENTIAL.
FT TRANSMEM 249 269 POTENTIAL.
FT TRANSMEM 307 327 POTENTIAL.
FT TRANSMEM 344 364 POTENTIAL.
FT TRANSMEM 373 393 POTENTIAL.
FT TRANSMEM 405 425 POTENTIAL.
FT TRANSMEM 447 467 POTENTIAL.
FT TRANSMEM 925 945 POTENTIAL.
FT TRANSMEM 1100 1120 POTENTIAL.
FT TRANSMEM 1144 1164 POTENTIAL.
FT TRANSMEM 1183 1203 POTENTIAL.
FT TRANSMEM 1213 1233 POTENTIAL.
FT TRANSMEM 1245 1265 POTENTIAL.
FT TRANSMEM 1306 1326 POTENTIAL.
FT NP_BIND 566 573 ATP (POTENTIAL).
FT NP_BIND 1416 1423 ATP (POTENTIAL).
FT CONFLICT 36 36 P -> S (IN REF. 2).
FT CONFLICT 196 196 L -> P (IN REF. 2).
SQ SEQUENCE 1704 AA; 191387 MW; AF0098DAF7A04F5F CRC64;

Query Match 25.1%; Score 84; DB 1; Length 1704;
Best Local Similarity 47.7%; Pred. No. 0.026;
Matches 21; Conservative 6; Mismatches 17; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLNKLTFRRTQCLLEVAWPLFLLISVRL 44
Db 1 MAVLRQLALLLNKNTLQKRRLVTVLELFLPLFPGLIWLRL 44

RESULT 5
FTSK_COXBU STANDARD; PRT; 778 AA.
ID FTSK_COXBU STANDARD; PRT; 778 AA.
AC F39920; 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE CELL DIVISION PROTEIN FTSK HOMOLOG.
GN FTSK OR SPOIIE.
OS Coxiella burnetii.
OC Bacteria; Proteobacteria; gamma subdivision; Legionellaceae group;
OC Coxiella group; Coxiella.
OX NCBI_TaxID=77;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=NINE MILE PHASE I / BRATISLAVA;
RX MEDLINE=94055499; PubMed=8237209;
RA Oswald W., Thiele D.;
RT "A sporulation gene in Coxiella burnetii?";
RL J. Vet. Med. B 40:366-370(1993).
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN (POTENTIAL).

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL: L43971; AAB00860.1; -
DR InterPro: IPR001225; -
DR Pfam: PF00487; FA_desaturase; 2.
KW Oxidoreductase; Fatty acid biosynthesis; Endoplasmic reticulum;
KW Transmembrane.
FT TRANSMEM 61 81 POTENTIAL.
FT TRANSMEM 85 105 POTENTIAL.
FT TRANSMEM 117 137 POTENTIAL.
FT TRANSMEM 179 199 POTENTIAL.
FT TRANSMEM 225 245 POTENTIAL.
FT TRANSMEM 249 269 POTENTIAL.
FT DOMAIN 105 109 HISTIDINE BOX 1.
FT DOMAIN 141 145 HISTIDINE BOX 2.
FT DOMAIN 315 319 HISTIDINE BOX 3.
SQ SEQUENCE 383 AA; 43967 MW; F23EF7159B2F9967 CRC64;

Query Match 17.5%; Score 58.5; DB 1; Length 383;
Best Local Similarity 28.6%; Pred. No. 6.8; Indels 5; Gaps 1;
Matches 10; Conservative 10; Mismatches 10;

QY 22 TCQLLEAVPFIILISVRLSPYPPEQHECHF 56
DQ 181 TLAVLTILGMPY-----LALNVSGRPYDFACHY 210

RESULT 8
SVL_NEUCR
ID SVL_NEUCR STANDARD; PRT; 1093 AA.
AC P28350;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE VALYL-TRNA SYNTHETASE, MITOCHONDRIAL PRECURSOR (EC 6.1.1.9)
DE (VALINE-TRNA LIGASE) (VALRS).
GN CYT-20 OR UN-3
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=74-OR23-1A;
RX MEDLINE=91304394; PubMed=1830127;
RA Kubelik A.R., Turcq B., Lambowitz A.M.;
RT "The Neurospora crassa cyt-20 gene encodes cytosolic and
RT mitochondrial valyl-cRNA synthetases and may have a second function
RT in addition to protein synthesis."
RL Mol. Cell. Biol. 11:4022-4035(1991).
CC -1- FUNCTION: MAY HAVE A SECOND FUNCTION IN ADDITION TO PROTEIN
CC SYNTHESIS.
CC -1- CATALYTIC ACTIVITY: ATP + L-VALINE + TRNA(VAL) = AMP +
CC PYROPHOSPHATE + L-VALYL-TRNA(VAL).
CC -1- SUBCELLULAR LOCATION: MITOCHONDRIAL AND CYTOPLASMIC.
CC -1- ALTERNATIVE PRODUCTS: A SINGLE NUCLEAR GENE PRODUCES BOTH FORMS
CC BY USE OF ALTERNATIVE INITIATION CODONS IN THE SAME READING FRAME.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL: M64703; -; NOT_ANNOTATED_CDS.
DR PIR: A41251; A41251.
DR InterPro: IPR001412; -
DR InterPro: IPR002300; -
DR InterPro: IPR002303; -
DR Pfam: PF00133; trna-synt_1; 1.
DR PRINTS: PRO00986; TRNASYNTHAL.
DR PROSITE: PS00178; AA-TRNA-LIGASE_I; 1.
KW Aminoacyl-tRNA synthetase; Protein biosynthesis; Ligase; ATP-binding;
KW Mitochondrion; Transit peptide; Alternative initiation.
FT TRANSIT 1 44 MITOCHONDRION.
FT CHAIN 45 1093 VALYL-TRNA SYNTHETASE, MITOCHONDRIAL
FT ISOFORM.
FT CHAIN 44 1093 VALYL-TRNA SYNTHETASE, CYTOPLASMIC
FT ISOFORM.
FT INIT_MET 44 44 FOR CYTOPLASMIC ISOFORM.
FT SITE 179 189 "HIGH" REGION.
FT SITE 692 696 "KMSKS" REGION.
FT BINDING 695 695 ATP (BY SIMILARITY).
FT MUTAGEN 201 201 R->C: GROSS DEFICIENCY OF BOTH MT AND
FT CYTOSOLIC VALRS ACTIVITIES.
SQ SEQUENCE 1093 AA; 123352 MW; 3492E40668CAB42C CRC64;

Query Match 17.1%; Score 57; DB 1; Length 1093;
Best Local Similarity 26.7%; Pred. No. 26;
Matches 16; Conservative 16; Mismatches 18; Indels 10; Gaps 5;

QY 4 WPQLRLLLW---KNLTFRRQTCLLLEAVPFIIF----LILSVRLS-YPPPEQHECH 55
DQ 625 WP-MAILGWPNTEMLDFKFPPTS-MLETGMDILFFWYRMILSLKMGVPEVYCH 682

RESULT 9
CYGF_BOVIN
ID CYGF_BOVIN STANDARD; PRT; 1103 AA.
AC O02740;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE RETINAL GUANYLYL CYCLASE 2 PRECURSOR (EC 4.6.1.2) (GUANYLYL CYCLASE
DE 2, RETINAL) (RETGC-2) (ROD OUTER SEGMENT MEMBRANE GUANYLYL CYCLASE
DE 2) (ROS-GC2) (GUANYLYL CYCLASE F) (GC-F).
GN GUCY2F OR GUC2F.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98238659; PubMed=9571173;
RA Goraczniak R.M., Duda T., Sharma R.K.;
RT "Calcium modulated signaling site in type 2 rod outer segment
RT membrane guanylate cyclase (ROS-GC2)."
RL Biochem. Biophys. Res. Commun. 245:447-453(1998).
CC -1- FUNCTION: PROBABLY PLAYS A SPECIFIC FUNCTIONAL ROLE IN THE RODS
CC AND/OR CONES OF PHOTORECEPTORS. IT MAY BE THE ENZYME INVOLVED IN
CC THE RESYNTHESIS OF CGMP REQUIRED FOR RECOVERY OF THE DARK STATE
CC AFTER PHOTOTRANSDUCTION (BY SIMILARITY).
CC -1- CATALYTIC ACTIVITY: GTP -> 3',5'-CYCLIC GMP + PYROPHOSPHATE.
CC -1- ENZYME REGULATION: ACTIVATED BY GCAP-1; INHIBITED BY CALCIUM.
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
CC -1- PTM: THERE ARE 9 CONSERVED CYSTEINE RESIDUES IN SENSORY GUANYLYL
CC CYCLASES, 6 IN THE EXTRACELLULAR DOMAIN, WHICH MAY BE INVOLVED IN
CC INTRA- OR INTERCHAIN DISULFIDE BONDS.
CC -1- SIMILARITY: BELONGS TO ADENYLYL CYCLASE CLASS-4/GUANYLYL CYCLASE
CC FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way

SQ SEQUENCE 436 AA; 51340 MW; 58051BFF59A4555F CRC64;
 Query Match 16.68; Score 55.5; DB 1; Length 436;
 Best Local Similarity 27.3%; Pred.No.17;
 Matches 12; Conservative 10; Mismatches 21; Indels 1; Gaps
 QY 14 NLTRRRQTCLLLEAVMPL-FIFILISVRLSYPPVEQHECHF 56
 Db 62 NITISTRATLYDQGVTDSPAIKFTLCQIDVRWFPDEQNCHF 105
 :|: |: |: |: |: |: |: |: |: |: |: |:
 RESULT 15
 ATSA_HUMAN STANDARD; PRT; 837 AA.
 ID ATSA_HUMAN
 AC Q75173; Q9UN83;
 DT 01-OCT-2000 (Rel. 40, Created)
 DT 01-OCT-2000 (Rel. 40, Last sequence update)
 DE 01-OCT-2000 (Rel. 40, Last annotation update)
 DE ADAM-TS 4 PRECURSOR (EC 3.4.24.-) (A DISINTEGRIN AND METALLOPROTEINASE
 WITH THROMBOSPONDIN MOTIFS 4) (ADAMTS-4) (ADAM-TS4) (AGGRECANASE 1)
 DE (ADMP-1).
 DE ADAMTS4 OR KIAA0688.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa;
 OC Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NCBI_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=98403880; PubMed=9734811;
 RA Ishikawa K.-I., Nagase T., Suyama M., Miyajima N., Tanaka A.,
 Kotani H., Nomura N., Ohara O.;
 RT "Prediction of the coding sequences of unidentified human genes. X.
 The complete sequences of 100 new cDNA clones from brain which can
 code for large proteins in vitro.";
 RL DNA Res. 5:169-176(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99286303; PubMed=10356395;
 RA Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M.,
 Liu R., Rosenfeld S.A., Copeland R.A., Decicco C.P., Wynn R.,
 Rockwell A., Yang F., Duke J.L., Solomon K., George H., Bruckner R.,
 Nagase H., Itoh Y., Ellis D.N., Ross H., Wiswall B.H., Murphy K.,
 Hillman M.C. Jr., Hollis G.F., Newton R.C., Magolda R.L.,
 Trzaskos J.M., Arner E.C.;
 RT "Purification and cloning of aggrecanase-1: a member of the ADAMTS
 family of proteases";
 RL Science 284:1664-1666(1999).
 RN [3]
 RP PARTIAL SEQUENCE, AND CHARACTERIZATION.
 RX MEDLINE=20400518; PubMed=10827174;
 RA Tortorella M., Pratta M., Liu R.Q., Abbaszade I., Ross H., Burn T.,
 Arner E.;
 RT "The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for
 aggrecan substrate recognition and cleavage";
 RL J. Biol. Chem. 275:25791-25797(2000).
 CC -1- FUNCTION: CLEAVES AGGREGAN, A CARTILAGE PROTEOGLYCAN, AND MAY BE
 INVOLVED IN ITS TURNOVER. MAY PLAY AN IMPORTANT ROLE IN THE
 DESTRUCTION OF AGGREGAN IN ARTHRITIC DISEASES.
 CC -1- CATALYTIC ACTIVITY: CLEAVES AGGREGAN AT THE 392-GLU-|-ALA-393
 SITE.
 CC COFACTOR: BINDS ONE ZINC ION (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: SECRETED. ASSOCIATED WITH THE EXTRACELLULAR
 MATRIX (BY SIMILARITY).
 CC -1- TISSUE SPECIFICITY: EXPRESSED IN BRAIN, LUNG AND HEART. EXPRESSED
 AT VERY LOW LEVEL IN PLACENTA AND SKELETAL MUSCLES.
 CC -1- INDUCTION: BY INTERLEUKIN 1.
 CC -1- DOMAIN: THE SPACER DOMAIN AND THE TSP TYPE 1 DOMAINS ARE IMPORTANT
 FOR A TIGHT INTERACTION WITH THE EXTRACELLULAR MATRIX.
 CC -1- PTM: THE PRECURSOR IS CLEAVED BY A FURIN ENDOPEPTIDASE.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M12B (ZINC
 METALLOPROTEASE); ALSO KNOWN AS THE REPROLYSIN SUBFAMILY

CC -!- SIMILARITY: CONTAINS 1 DISINTEGRIN-LIKE DOMAIN.
CC -!- SIMILARITY: CONTAINS 1 TSP TYPE-1 DOMAIN.
CC -!- CAUTION: HAS SOMETIMES BEEN REFERRED TO ADAMTS2.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AB014588; BAA31663.1; -;
DR EMBL; AF148213; AAD41494.1; -;
DR MIM; 603876; -;
DR HSP; P34179; LIAG.
DR MEROPS; M12.221; -;
DR InterPro; IPR000130; -;
DR InterPro; IPR000884; -;
DR InterPro; IPR001590; -;
DR Pfam; PF00090; tsp.1; 1.
DR Pfam; PF01421; Repolysin; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; 1.
DR PROSITE; PS0215; ADAM_MEPRO; 1.
DR PROSITE; PS0092; TSP1; 1.
DR PROSITE; PS00427; DISINTEGRINS; FALSE_NEG.
KW Hydrolase; Metalloprotease; Zinc; Signal; Glycoprotein; Zymogen;
KW Extracellular matrix.
FT SIGNAL 1 51 POTENTIAL.
FT PROPEP 52 212
FT CHAIN 213 837 ADAM-TS 4.
FT SITE 194 194 CYSTEINE SWITCH (POTENTIAL).
FT METAL 361 361 ZINC (CATALYTIC) (BY SIMILARITY).
FT ACT_SITE 362 362 BY SIMILARITY.
FT METAL 365 365 ZINC (CATALYTIC) (BY SIMILARITY).
FT METAL 371 371 ZINC (CATALYTIC) (BY SIMILARITY).
FT DOMAIN 437 519 DISINTEGRIN-LIKE.
FT DOMAIN 520 576 TSP-TYPE 1 1.
FT DOMAIN 577 685 CYS-RICH.
FT DOMAIN 686 837 SPACER.
FT DOMAIN 247 252 POLY-ALA.
FT CARBOHYD 68 68 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 77 77 A -> T (IN REF. 1).
SQ SEQUENCE 837 AA; 90224 MW; 5DF9C9AC137DF41F CRC64;

Query Match 16.6%; Score 55.5; DB 1; Length 837;
Best Local Similarity 32.6%; Pred. No. 31;
Matches 15; Conservative 10; Mismatches 14; Indels 7; Gaps 2;

OY 21 QTCOLL--LEVAMPFLIFLILI-----SVRLSYPPYEQHECHFPNK 59
| | | : : : : : | | | : : : : :
Db 21 QPCLLPIVPLSLVWLLLLLASLLPSARLASPLPREETVPEK 66

Search completed: May 31, 2001, 13:08:58
Job time: 299 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:13:49 ; Search time 39.12 Seconds
(without alignments)
105.403 Million cell updates/sec

Title: US-09-526-193a-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKWLTKRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 198801 seqs, 68722935 residues

Total number of hits satisfying chosen parameters: 198801

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR_67:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	86	25.7	1704	2 S71363	probable ATP-bind
2	84	25.1	1704	2 A59188	ATP-binding casset
3	71.5	21.4	707	2 T09340	hypothetical prote
4	65.5	19.6	778	2 S43132	sporulation protei
5	60.5	18.1	511	2 T43634	nicotinic acetylch
6	60.5	18.1	534	2 T27220	hypothetical prote
7	60.5	18.1	598	2 T05130	hypothetical prote
8	60	18.0	1802	2 T33783	hypothetical prote
9	59.5	17.8	466	2 PC4296	nicotinic acetylch
10	58.5	17.5	383	2 T07688	omega-6 desaturase
11	58	17.4	250	2 D75317	hypothetical prote
12	57	17.1	1093	2 A41251	valine--trNA ligas
13	57	17.1	1103	2 JC5581	guanylate cyclase
14	56.5	16.9	1400	2 T22644	hypothetical prote
15	56.5	16.9	1977	2 S54771	sodium channel alp
16	56.5	16.9	3268	2 S69625	hypothetical prote
17	56	16.8	373	2 JC7289	G-protein coupled
18	56	16.8	463	2 B56849	dopamine receptor-
19	56	16.8	512	2 E81938	probable apolipop
20	56	16.8	524	2 H81166	apolipoprotein N-a
21	56	16.8	830	2 T04848	protein kinase hom
22	56	16.8	921	1 A40981	3',5'-cyclic-nucle
23	56	16.8	1215	2 B72029	helicase, Snf2/Rad
24	56	16.8	2201	2 A54774	ATP binding casset
25	55.5	16.6	299	2 F83301	conserved hypothet
26	55.5	16.6	372	2 T20289	hypothetical prote
27	55.5	16.6	378	2 T14269	delta12 fatty acid
28	55.5	16.6	495	2 G70852	hypothetical prote
29	55.5	16.6	706	2 T20052	hypothetical prote

30	55.5	16.6	837	2 T00355	hypothetical prote
31	55	16.5	293	2 T32229	hypothetical prote
32	55	16.5	357	2 H64855	probable membrane
33	55	16.5	928	1 JC2486	3',5'-cyclic-nucle
34	55	16.5	1976	2 T56555	sodium channel pro
35	54.5	16.3	383	2 T10480	delta12 fatty acid
36	54.5	16.3	454	2 T32974	hypothetical prote
37	54	16.2	401	2 B83369	conserved hypothet
38	54	16.2	442	2 A83743	magnesium citrate
39	54	16.2	547	2 S61032	hypothetical prote
40	54	16.2	825	2 T27852	hypothetical prote
41	54	16.2	2005	2 B25019	sodium channel alp
42	54	16.2	2005	2 A46369	sodium channel alp
43	53.5	16.0	333	2 T65989	G protein-coupled
44	53.5	16.0	538	2 D82180	probable sensor ki
45	53.5	16.0	778	2 T05341	S-receptor kinase

ALIGNMENTS

RESULT 1

S71363

Probable ATP-binding cassette transporter ABC-3 - human

N;Alternate names: ATP-binding cassette transporter ABC-C

C:Species: Homo sapiens (man)

C>Date: 29-Jan-1998 #sequence_revision 06-Feb-1998 #text_change 17-Mar-2000

C:Accession: S71363

R:Klugbauer, N.; Hofmann, F.

FEBS Lett. 391, 61-65, 1996

A:Title: Primary structure of a novel ABC transporter with a chromosomal localization

A:Reference number: S71363; MUID:96326608

A:Accession: S71363

A:Status: nucleic acid sequence not shown

A:Molecule type: mRNA

A:Residues: 1-1704 <KLU>

A:Cross-references: EMBL:X97187; NID:q1514529; PIDN:CAA65825.1; PID:e243436; PID:q151

A:Experimental source: cell line medullary thyroid carcinoma

C:Genetics:

A:Gene: GDB:ABC3

A:Cross-references: GDB:3770735; OMIM:601615

A:Map position: 16p13.3-16p13.3

C:Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog

C:Keywords: ATP binding; P-loop; phosphoprotein; transmembrane protein

F:255-283/Domain: transmembrane #status predicted <TM1>

F:307-329/Domain: transmembrane #status predicted <TM2>

F:345-364/Domain: transmembrane #status predicted <TM3>

F:373-394/Domain: transmembrane #status predicted <TM4>

F:401-422/Domain: transmembrane #status predicted <TM5>

F:452-475/Domain: transmembrane #status predicted <TM6>

F:549-739/Domain: ATP-binding cassette homolog <ABC1>

F:566-573/Region: nucleotide-binding motif A (P-loop)

F:685-690/Region: nucleotide-binding motif B

F:1100-1120/Domain: transmembrane #status predicted <TM7>

F:1145-1169/Domain: transmembrane #status predicted <TM8>

F:1181-1207/Domain: transmembrane #status predicted <TM9>

F:1215-1236/Domain: transmembrane #status predicted <TM10>

F:1245-1264/Domain: transmembrane #status predicted <TM11>

F:1299-1324/Domain: transmembrane #status predicted <TM12>

F:1399-1590/Domain: ATP-binding cassette homolog <ABC2>

F:1416-1423/Region: nucleotide-binding motif A (P-loop)

F:1535-1540/Region: nucleotide-binding motif B

F:674,866,1524/Binding site: phosphate (Ser) (covalent) (by CAMP-dependent kinase) #s

F:1344/Binding site: phosphate (Thr) (covalent) (by CAMP-dependent kinase) #status pr

Query Match 25.7%; Score 86; DB 2; Length 1704;

Best Local Similarity 47.7%; Pred. No. 0.016; Mismatches 17; Indels 0; Gaps 0;

Matches 21; Conservative 6;

OY 1 MACWPQLRLLLKWLTKRRRQCQLLEAVAMPFLFILISVRL 44

DB 1 MAVLRQLALLLWKNTYTKRKVLTVLEFLPLFSGILWLRL 44

```

Query Match      18.1%; Score 60.5; DB 2; Length 534;
Best Local Similarity 27.9%; Pred. No. 7.4;
Matches 12; Conservative 10; Mismatches 20; Indels 1; Gaps 1;
QY 14 NLTPRRQTCOLLLEVAW-PLTFILILISVRLSYPPVEQHECH 55

```


Search completed: May 31, 2001, 13:05:24
Job time: 2735 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 13:03:19 ; Search time 54.28 seconds
(without alignments)
14.331 Million cell updates/sec

Title: US-09-526-193a-l_copy_l_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLKLNLTFRRT.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 280389 seqs, 12964817 residues

Total number of hits satisfying chosen parameters: 280389

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_AA_New.*

1: /cgn2_6/ptodata/2/paa/PCT_NEW_COMB.pcp.*
2: /cgn2_6/ptodata/2/paa/US05_NEW_COMB.pcp.*
3: /cgn2_6/ptodata/2/paa/US07_NEW_COMB.pcp.*
4: /cgn2_6/ptodata/2/paa/US08_NEW_COMB.pcp.*
5: /cgn2_6/ptodata/2/paa/US09_NEW_COMB.pcp.*
6: /cgn2_6/ptodata/2/paa/US60_NEW_COMB.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	334	100.0	2261	1	PCT-US01-04098A-1212
2	334	100.0	2261	5	US-09-526-193A-1
3	334	100.0	2263	1	PCT-US01-04098A-3180
4	205	61.4	302	1	PCT-US01-11988-908
5	205	61.4	302	5	US-09-833-245-908
6	117	35.0	21	5	US-09-526-193A-37
7	62.5	18.7	774	6	US-60-248-505-1176
8	56.5	16.9	551	1	PCT-US01-04098A-1326
9	56.5	16.9	595	1	PCT-US01-04098A-3294
10	56	16.8	284	1	PCT-US01-01310-71
11	56	16.8	378	1	PCT-US01-01310-77
12	53	15.9	183	1	PCT-US01-01310-102
13	53	15.9	183	1	PCT-US01-01332-806
14	53	15.9	370	5	US-09-383-745-1
15	53	15.9	379	1	PCT-US01-01310-79
16	53	15.9	586	6	US-60-248-505-1178
17	52	15.6	191	5	US-09-811-284-161
18	52	15.6	695	6	US-60-248-505-696
19	51.5	15.4	333	5	US-09-826-509-509
20	51	15.3	269	5	US-09-383-745-3
21	50.5	15.1	446	5	US-09-826-509-487
22	50.5	15.1	1422	4	US-08-467-344A-81
23	50	15.0	150	1	PCT-US01-03782A-115
24	50	15.0	366	1	PCT-US01-11988-2066
25	50	15.0	366	5	US-09-781-417-46
26	50	15.0	366	5	US-09-833-245-2066
27	49.5	14.8	319	1	PCT-US01-04098A-1067

ALIGNMENTS

RESULT 1

PCT-US01-04098A-1212
; Sequence 1212, Application PC/TUS0104098A
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-029
; CURRENT APPLICATION NUMBER: PCT/US01/04098A
; CURRENT FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: Not Yet Assigned
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/728,422
; PRIOR FILING DATE: 2000-11-30
; PRIOR APPLICATION NUMBER: 09/693,325
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/663,561
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/654,936
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 09/620,325
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/598,075
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 09/560,875
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 09/496,914
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 3960
; SOFTWARE: Custom
; SEQ ID NO 1212
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-04098A-1212

Query Match 100.0%; Score 334; DB 1; Length 2261;
Best Local Similarity 100.0%; Pred. No. 1.4e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLKLNLTFRRTQCLLLEAVMPLEFIFILISVRLSYPPYEQHECHFPNKA 60

Db 1 MACWPQLRLLLKLNLTFRRTQCLLLEAVMPLEFIFILISVRLSYPPYEQHECHFPNKA 60

RESULT 2

US-09-526-193A-1
; Sequence 1, Application US/09526193A
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.


```

Qy      41  SVRLSYPPYEQHECHFPNKA   60
          |||||
Db      2  SVRLSYPPYEQHECHFPNKA   21

RESULT       7
US-60-248-505-1176
; Sequence 1176, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15

```

```

RESULT      8
PCT-US01-04098A-1326
; Sequence 1326, Application PC/TUS0104098A
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-029
; CURRENT APPLICATION NUMBER: PCT/US01/04098A
; CURRENT FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: Not Yet Assigned
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/728,422
; PRIOR FILING DATE: 2000-11-30
; PRIOR APPLICATION NUMBER: 09/693,325
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 09/663,561
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/654,936
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 09/620,325
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 09/598,075
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 09/560,875
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 09/496,914
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 3960
; SOFTWARE: Custom
; SEQ ID NO 1326
; LENGTH: 551
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US01-04098A-1326

```

```

RESULT          9
PCT-US01-04098A-3294
; Sequence 3294, Application PC/TUS0104098A
; GENERAL INFORMATION:
;   APPLICANT: Hyseq, Inc.
;   TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides

```

RESULT	11
PCT-US01-0	

: NUMBER OF SEO ID NOS: 1249

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:20:09 ; Search time 92.94 Seconds
(without alignments)
103.844 Million cell updates/sec

Title: US-09-526-193A-1_COPY_1_60
Perfect score: 334
Sequence: 1 MACWPQLRLLLWNLTFRRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1009251 seqs, 160854530 residues

Total number of hits satisfying chosen parameters: 1009251

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_AA_Main : *
1: /cgn2_6/ptodata/1/paa/PCTUS_COMB.pep.*
2: /cgn2_6/ptodata/1/paa/US06_COMB.pep.*
3: /cgn2_6/ptodata/1/paa/US07_COMB.pep.*
4: /cgn2_6/ptodata/1/paa/US080_COMB.pep.*
5: /cgn2_6/ptodata/1/paa/US081_COMB.pep.*
6: /cgn2_6/ptodata/1/paa/US082_COMB.pep.*
7: /cgn2_6/ptodata/1/paa/US083_COMB.pep.*
8: /cgn2_6/ptodata/1/paa/US084_COMB.pep.*
9: /cgn2_6/ptodata/1/paa/US085_COMB.pep.*
10: /cgn2_6/ptodata/1/paa/US086_COMB.pep.*
11: /cgn2_6/ptodata/1/paa/US087_COMB.pep.*
12: /cgn2_6/ptodata/1/paa/US088_COMB.pep.*
13: /cgn2_6/ptodata/1/paa/US089_COMB.pep.*
14: /cgn2_6/ptodata/1/paa/US090_COMB.pep.*
15: /cgn2_6/ptodata/1/paa/US091_COMB.pep.*
16: /cgn2_6/ptodata/1/paa/US092_COMB.pep.*
17: /cgn2_6/ptodata/1/paa/US093_COMB.pep.*
18: /cgn2_6/ptodata/1/paa/US094_COMB.pep.*
19: /cgn2_6/ptodata/1/paa/US095_COMB.pep.*
20: /cgn2_6/ptodata/1/paa/US096_COMB.pep.*
21: /cgn2_6/ptodata/1/paa/US097_COMB.pep.*
22: /cgn2_6/ptodata/1/paa/US098_COMB.pep.*
23: /cgn2_6/ptodata/1/paa/US60_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	334	100.0	162	23	US-60-169-629-486
2	334	100.0	162	23	US-60-187-470-486
3	334	100.0	2261	1	PCT-US00-06745-1
4	334	100.0	2261	19	US-09-526-193-1
5	334	100.0	2261	20	US-09-654-323-5
6	230	68.9	101	23	US-60-206-111-183
7	230	68.9	145	1	PCT-US00-30628A-175
8	230	68.9	2083	23	US-60-230-445-1448
9	230	68.9	2180	23	US-60-221-839-5
10	230	68.9	2180	23	US-60-230-445-2002

11	205	61.4	302	1	PCT-US00-30628A-101	Sequence 101, App
12	180	53.9	145	1	PCT-US00-30628A-178	Sequence 178, App
13	180	53.9	1446	23	US-60-258-275-311	Sequence 311, App
14	180	53.9	2235	14	US-09-032-438-6	Sequence 6, Appli
15	180	53.9	2273	14	US-09-032-438-3	Sequence 3, Appli
16	120	35.9	1875	23	US-60-230-445-1535	Sequence 1535, Ap
17	117	35.0	21	1	PCT-US00-06745-37	Sequence 37, Appl
18	117	35.0	21	19	US-09-526-193-37	Sequence 37, Appl
19	104	31.1	210	23	US-60-213-846-938	Sequence 938, App
20	104	31.1	2436	21	US-09-795-693-8	Sequence 8, Appli
21	104	31.1	2436	23	US-60-232-685-2	Sequence 2, Appli
22	103	30.8	2436	1	PCT-US00-40789-2	Sequence 2, Appli
23	86	25.7	1704	11	US-08-720-614-75	Sequence 75, Appl
24	86	25.7	2319	23	US-60-207-583-427	Sequence 427, App
25	86	25.7	2431	23	US-60-230-445-1964	Sequence 1964, Ap
26	86	25.7	3040	23	US-60-230-445-1210	Sequence 1210, Ap
27	78	23.4	1713	23	US-60-171-625-45	Sequence 45, Appl
28	78	23.4	1713	23	US-60-173-464-1728	Sequence 1728, Ap
29	78	23.4	1713	23	US-60-191-637-2064	Sequence 2064, Ap
30	78	23.4	1713	23	US-60-191-681-1647	Sequence 1647, Ap
31	78	23.4	1713	23	US-60-219-005-18	Sequence 18, Appl
32	70	21.0	100	23	US-60-147-499-4269	Sequence 4269, Ap
33	70	21.0	101	23	US-60-197-873-17098	Sequence 17098, A
34	70	21.0	1642	23	US-60-223-269-3	Sequence 3, Appli
35	63	18.9	63	1	PCT-US01-01354-13508	Sequence 13508, A
36	62.5	18.7	426	23	US-60-207-583-607	Sequence 607, App
37	62.5	18.7	426	23	US-60-230-445-1682	Sequence 1682, Ap
38	61.5	18.4	2271	23	US-60-173-464-27974	Sequence 27974, A
39	61.5	18.4	2272	23	US-60-191-637-36418	Sequence 36418, A
40	61.5	18.4	2272	23	US-60-191-681-28456	Sequence 28456, A
41	61	18.3	218	23	US-60-161-932-2601	Sequence 2601, Ap
42	60.5	18.1	464	18	US-09-450-969-4444	Sequence 4444, Ap
43	60.5	18.1	529	18	US-09-413-198-2403	Sequence 2403, Ap
44	59.5	17.8	181	18	US-09-417-507-38344	Sequence 38344, A
45	59.5	17.8	224	1	PCT-US93-09987-10	Sequence 10, Appl

ALIGNMENTS

RESULT 1
US-60-169-629-486
; Sequence 486, Application US/60169629
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Bougueleret, L.
; TITLE OF INVENTION: CDNAS for Secreted Proteins
; FILE REFERENCE: GENSET.071PRF
; CURRENT APPLICATION NUMBER: US/60/169,629
; CURRENT FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 715
; SOFTWARE: Patent.pm
; SEQ ID NO 486
; LENGTH: 162
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -47..-1
US-60-169-629-486

Query Match	100.0%	Score 334;	DB 23;	Length 162;
Best Local Similarity	100.0%	Pred. NO. 2.8e-31;		
Matches	60;	Conservative	0;	Mismatches 0;
Indels	0;	Gaps	0;	
QY	1	MACWPQLRLLLWNLTFRRRQTCOLLEVAWPLFIILISVRLSYPPYEQHECHFPNKA	60	
DB	1	MACWPQLRLLLWNLTFRRRQTCOLLEVAWPLFIILISVRLSYPPYEQHECHFPNKA	60	
RESULT	2			

```

Query Match      100.0%; Score 334; DB 20; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.6e-30;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps
QY      1 MACWQQLRLLLWKNLTFRRTQTCOLLELVAMPFLFELILISVRLSYPPYEQHECHFPNKA 60
      |||||

```

```

; CURRENT FILING DATE: 2000-09-06
; NUMBER OF SEQ ID NOS: 3051
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1448
; LENGTH: 2083
; TYPE: PRT
; ORGANISM: HUMAN
US-60-230-445-1448

Query Match      68.9%; Score 230; DB 23; Length 2083;
Best Local Similarity 67.8%; Pred. No. 3.5e-18;
Matches 40; Conservative 7; Mismatches 12; Indels 0; Gap

Qy 1 MACPQLRLLLKNTLRRRQTCQLLEAVAMPFLFIFLIISVRLSYPPYEQHECHFPNK 59
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 MAFWTQLMLLLKNTLRRRQTCQLLEAVAMPFLFIFLIISVRLSYPPYEQHECHFPNK 59

RESULT 9
US-60-221-839-5
; Sequence 5, Application US/60221839
; GENERAL INFORMATION:
; APPLICANT: Lal, Preeti
; APPLICANT: Yue, Henry
; APPLICANT: Walia, Narinder K.
; APPLICANT: Baughn, Mariah R.
; APPLICANT: Tribouley, Catherine M.
; APPLICANT: Yang, Junming
; APPLICANT: Thornton, Michael
; APPLICANT: Hafalia, April
; APPLICANT: Patterson, Chandra
; APPLICANT: Greene, Barrie D.
; APPLICANT: Yao, Monique G.
; APPLICANT: Raumann, Brigitte E.
; APPLICANT: Gandhi, Ameena R.
; APPLICANT: Lu, Yan
; APPLICANT: Ding, Li
; APPLICANT: Tang, Y. Tom
; APPLICANT: Azimzai, Yalda
; APPLICANT: Burford, Neil
; APPLICANT: Sellhamer, Jeffrey J.
; APPLICANT: Borowsky, Mark L.
; APPLICANT: Nguyen, Dannel B.
; APPLICANT: Khan, Farrah A.
; APPLICANT: Elliott, Vicki S.
; APPLICANT: Kearney, Liam
; APPLICANT: Lu, Dyung Aina M.
; APPLICANT: Thangavelu, Kavitha
; APPLICANT: Xu, Yuming
; APPLICANT: Sanjanwala, Madhu Sudan
; APPLICANT: Das, Debopriya
; APPLICANT: Policy, Jennifer L.
; TITLE OF INVENTION: TRANSPORTERS AND ION CHANNELS
; FILE REFERENCE: PI-0170 P
; CURRENT APPLICATION NUMBER: US/60/221,839
; CURRENT FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PERL Program
; SEQ ID NO 5:
; LENGTH: 2180
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 7475603CD1
US-60-221-839-5

Query Match      68.9%; Score 230; DB 23; Length 2180;
Best Local Similarity 67.8%; Pred. No. 3.6e-18;
Matches 40; Conservative 7; Mismatches 12; Indels 0; Gap

```

QY 1 MACHPQLRLLLKKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 59
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 Db 35 MAFTQMLLLKKNLFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 93
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 RESULT 10
 US-60-230-445-2002
 ; Sequence 2002, Application US/60230445
 ; GENERAL INFORMATION:
 ; APPLICANT: Beasley, Ellen
 ; TITLE OF INVENTION: ISOLATED HUMAN TRANSPORTER PROTEINS,
 ; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS,
 ; TITLE OF INVENTION: AND USES THEREOF
 ; FILE REFERENCE: CL000765
 ; CURRENT APPLICATION NUMBER: US/60/230,445
 ; CURRENT FILING DATE: 2000-09-06
 ; NUMBER OF SEQ ID NOS: 3051
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 2002
 ; LENGTH: 2180
 ; TYPE: PRT
 ; ORGANISM: HUMAN
 ; PCT-US00-230-445-2002

Query Match 68.9%; Score 230; DB 23; Length 2180;
 Best Local Similarity 67.8%; Pred. No. 3.6e-18;
 Matches 40; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

QY 1 MACHPQLRLLLKKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 59
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 Db 1 MAFTQMLLLKKNLFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 59
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||

RESULT 11
 PCT-US00-30628A-101
 ; Sequence 101, Application PC/TUS0030628A
 ; GENERAL INFORMATION:
 ; APPLICANT: Human Genome Sciences, Inc.
 ; TITLE OF INVENTION: 28 Human Secreted Proteins
 ; FILE REFERENCE: PS712PCT
 ; CURRENT APPLICATION NUMBER: PCT/US00/30628A
 ; CURRENT FILING DATE: 2000-11-08
 ; PRIOR APPLICATION NUMBER: 60/164,744
 ; PRIOR FILING DATE: 1999-11-12
 ; PRIOR APPLICATION NUMBER: 60/215,140
 ; PRIOR FILING DATE: 2000-06-30
 ; NUMBER OF SEQ ID NOS: 190
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 101
 ; LENGTH: 302
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: SITE
 ; LOCATION: (262)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; NAME/KEY: SITE
 ; LOCATION: (279)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; NAME/KEY: SITE
 ; LOCATION: (294)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; NAME/KEY: SITE
 ; LOCATION: (295)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; PCT-US00-30628A-101

Query Match 61.4%; Score 205; DB 1; Length 302;
 Best Local Similarity 68.6%; Pred. No. 5.5e-16;
 Matches 35; Conservative 7; Mismatches 9; Indels 0; Gaps 0;

QY 9 LLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 59
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 Db 2 LLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 52
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||

RESULT 12
 PCT-US00-30628A-178
 ; Sequence 178, Application PC/TUS0030628A
 ; GENERAL INFORMATION:
 ; APPLICANT: Human Genome Sciences, Inc.
 ; TITLE OF INVENTION: 28 Human Secreted Proteins
 ; FILE REFERENCE: PS712PCT
 ; CURRENT APPLICATION NUMBER: PCT/US00/30628A
 ; CURRENT FILING DATE: 2000-11-08
 ; PRIOR APPLICATION NUMBER: 60/164,744
 ; PRIOR FILING DATE: 1999-11-12
 ; PRIOR APPLICATION NUMBER: 60/215,140
 ; PRIOR FILING DATE: 2000-06-30
 ; NUMBER OF SEQ ID NOS: 190
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 178
 ; LENGTH: 145
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; PCT-US00-30628A-178

Query Match 53.9%; Score 180; DB 1; Length 145;
 Best Local Similarity 56.4%; Pred. No. 2.5e-13;
 Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 6 QLRLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 60
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 Db 6 QIQLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 60
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||

RESULT 13
 US-60-258-275-311
 ; Sequence 311, Application US/60258275
 ; GENERAL INFORMATION:
 ; APPLICANT: Beasley, Ellen
 ; TITLE OF INVENTION: ISOLATED HUMAN TRANSPORTER PROTEINS,
 ; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS,
 ; TITLE OF INVENTION: AND USES THEREOF
 ; FILE REFERENCE: CL001026-PROV
 ; CURRENT APPLICATION NUMBER: US/60/258,275
 ; CURRENT FILING DATE: 2000-12-27
 ; NUMBER OF SEQ ID NOS: 717
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 311
 ; LENGTH: 1446
 ; TYPE: PRT
 ; ORGANISM: HUMAN
 ; US-60-258-275-311

Query Match 53.9%; Score 180; DB 23; Length 1446;
 Best Local Similarity 56.4%; Pred. No. 1.8e-12;
 Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 6 QLRLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 60
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||
 Db 32 QIQLLWKNLTFRRTQTCOLLLEVAWPLFIPLILISVRLSYPPYEQHECHFPNK 86
 ||||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :|||| :||||

RESULT 14
 US-09-032-438-6
 ; Sequence 6, Application US/09032438
 ; GENERAL INFORMATION:
 ; APPLICANT: Allikmets, Rando, Anderson, Kent L., Dean, Michael, Leppert,
 ; APPLICANT: Mark, Lewis, Richard A., Li, Yixin, Lupski, James R., Nathans, Jerem
 ; APPLICANT: Amir, Shroyer, Noah F., Singh, Nanda, Smallwood, Philip, M., Sun, Hu
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES

```

; APPLICATION NUMBER: US/09/032.438
; FILING DATE: 27-FEB-1998
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y
; REGISTRATION NUMBER: 34,293
; REFERENCE/DOCKET NUMBER: BYLR-0065
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2273 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-032-438-3

Query Match          53.9%; Score 180; DB 14; Length 2273;
Best Local Similarity 56.4%; Pred. No. 2.6e-12;
Matches 31; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY      6 QRLRLLNKLTFRRCQCLLLEVAWPLFLILISVRLSYPPPEQHCHFPNKA 60
       |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      6 QIQLLLKNWTLRKRQIRFYVELVWPLSLFLVLILRNANPLYSHHCHFPNKA 60

Search completed: May 31, 2001, 13:07:08
Job time: 2819 sec

```


GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:18:09 ; Search time 25.08 seconds
(without alignments)
45.959 Million cell updates/sec

Title: US-09-526-193a-1_COPY_1_60
Perfect score: 334

Sequence: 1 MACWPQLRLLLNKLTFR...SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 185757 seqs, 19210857 residues

Total number of hits satisfying chosen parameters: 185757

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents_AA:*
1: /cgn2_6/ptodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/PTCUS_COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB ID	Description
1	86	25.7	1704	3	US-08-762-500-75
2	58.5	17.5	382	3	US-08-811-177A-2
3	58	17.4	382	2	US-08-872-302-2
4	56.5	16.9	1969	4	US-08-836-325-16
5	56	16.8	921	1	US-07-872-644-39
6	56	16.8	921	1	US-08-297-494-39
7	56	16.8	921	1	US-08-297-510-39
8	56	16.8	921	1	US-08-479-532-39
9	56	16.8	921	1	US-08-455-526-39
10	56	16.8	921	1	US-08-455-525-39
11	56	16.8	921	3	US-09-139-491-39
12	56	16.8	921	5	PCT-US92-03222-39
13	56	16.8	941	1	US-07-872-644-45
14	56	16.8	941	1	US-08-297-494-45
15	56	16.8	941	1	US-08-297-510-45
16	56	16.8	941	1	US-08-479-532-45
17	56	16.8	941	1	US-08-455-526-45
18	56	16.8	941	1	US-08-455-525-45
19	56	16.8	941	3	US-09-139-491-45
20	56	16.8	941	5	PCT-US92-03222-45
21	56	16.8	942	1	US-07-872-644-43
22	56	16.8	942	1	US-08-297-494-43
23	56	16.8	942	1	US-08-297-510-43
24	56	16.8	942	1	US-08-479-532-43
25	56	16.8	942	1	US-08-455-526-43
26	56	16.8	942	1	US-08-455-525-43
27	56	16.8	942	3	US-09-139-491-43

Sequence 43, Appl
Sequence 26, Appl
Sequence 26, Appl
Sequence 6, Appl
Sequence 41, Appl
Sequence 41, Appl
Sequence 9, Appl
Sequence 2, Appl
Sequence 4, Appl
Sequence 4, Appl
Sequence 2, Appl
Sequence 10, Appl
Sequence 12, Appl
Sequence 2, Appl
Sequence 7, Appl
Sequence 40, Appl
Sequence 42, Appl
Sequence 40, Appl

28 56 16.8 942 5 PCT-US92-03222-43
29 56 16.8 1375 3 US-08-665-259-26
30 56 16.8 1375 3 US-08-762-500-26
31 55 16.5 232 3 US-09-024-020B-6
32 55 16.5 383 1 US-08-314-596-41
33 55 16.5 383 1 US-08-320-982-41
34 55 16.5 383 3 US-08-819-037-41
35 55 16.5 1976 3 US-09-024-020B-9
36 55 16.5 1978 3 US-09-024-020B-3
37 55 16.5 1988 3 US-09-024-020B-4
38 54.5 16.3 1011 4 US-08-836-325-2
39 54.5 16.3 1984 4 US-08-836-325-10
40 54.5 16.3 1989 4 US-08-836-325-12
41 53 15.9 370 3 US-09-251-373-2
42 53 15.9 2005 4 US-08-836-325-7
43 52.5 15.7 387 1 US-08-314-596-40
44 52.5 15.7 387 1 US-08-314-596-42
45 52.5 15.7 387 1 US-08-320-982-40

ALIGNMENTS

RESULT 1
US-08-762-500-75
; Sequence 75, Application US/08762500
; Patent No. 6030806
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Burn, Timothy C.
; APPLICANT: Connors, Timothy D.
; APPLICANT: Dackowski, William R.
; APPLICANT: Van Ruy, Terence J.
; APPLICANT: Klingner, Katherine W.
; TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
; TITLE OF INVENTION: COMPOSITIONS, METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 83
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GENZYME CORPORATION
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: United States of America
; ZIP: 01701

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/762,500
FILING DATE: 09-DEC-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/665,259
FILING DATE: 17-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/10469
FILING DATE: 17-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IG5-9.3
TELEPHONE: (508) 872-8400
TELEFAX: (508) 872-5415
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 1704 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-762-500-75

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;


```
;
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,526
; FILING DATE: 31-MAY-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/297,494
; FILING DATE: 29-AUG-1994
; APPLICATION NUMBER: US 07/688,356
; FILING DATE: 04-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5789553and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30822
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
; TELEFAX: (312) 984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 921 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-455-526-39

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels 4; Gaps 1;

Qy 3 CWPQLRLLLKKNLFRFRQ----TCQLLEVAWPLFIILISVRL 44
|: | | | | | | | | | | | | | | | | | | | |
Db 349 CFHYTSTVLTSLAFQKEQKLKCECQALLQVAKNLFTHLDDVSLL 394

RESULT 10
US-08-455-525-39
; Sequence 39, Application US/08455525
; Patent No. 5800987
; GENERAL INFORMATION:
; APPLICANT: Beavo, Joseph A.
; APPLICANT: Bentley, Kelley
; APPLICANT: Charbonneau, Harry
; APPLICANT: Sonnenburg, William K.
; TITLE OF INVENTION: DNA Encoding Mammalian
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,525
; FILING DATE: 31-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
```

```
;
; APPLICATION NUMBER: 08/297,494
; FILING DATE:
; APPLICATION NUMBER: US 07/688,356
; FILING DATE: 04-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5800987and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30822
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
; TELEFAX: (312) 984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 921 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-455-525-39

Query Match 16.8%; Score 56; DB 1; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels 4; Gaps 1;

Qy 3 CWPQLRLLLKKNLFRFRQ----TCQLLEVAWPLFIILISVRL 44
|: | | | | | | | | | | | | | | | | | | | |
Db 349 CFHYTSTVLTSLAFQKEQKLKCECQALLQVAKNLFTHLDDVSLL 394

RESULT 11
US-09-139-491-39
; Sequence 39, Application US/09139491
; Patent No. 6015677
; GENERAL INFORMATION:
; APPLICANT: Beavo, Joseph A.
; APPLICANT: Bentley, Kelley
; APPLICANT: Charbonneau, Harry
; APPLICANT: Sonnenburg, William K.
; TITLE OF INVENTION: DNA Encoding Mammalian
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/139,491
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,525
; FILING DATE: 31-MAY-1995
; APPLICATION NUMBER: 08/297,494
; FILING DATE:
; APPLICATION NUMBER: US 07/688,356
; FILING DATE: 04-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6015677and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30822
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
```

Query Match 16.8%; Score 56; DB 5; Length 921;
Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels

APPLICANT: Charbonneau

```

RESULT 15
US-08-297-510-45
; Sequence 45, Application US/08297510
; Patent No. 5602019
; GENERAL INFORMATION:
; APPLICANT: Beavo, Joseph A.
; APPLICANT: Bentley, Kelley
; APPLICANT: Charbonneau, Harry
; APPLICANT: Sonnenburg, William K.
; TITLE OF INVENTION: DNA Encoding Mammalian
; TITLE OF INVENTION: Phosphodiesterases
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
;

```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/297,510
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/688,356
; FILING DATE: 04-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5602019and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30822
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
; TELEFAX: (312) 984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 941 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-297-510-45

Query Match 16.8%; Score 56; DB 1; Length 941;
Best Local Similarity 37.0%; Pred. No. 18;
Matches 17; Conservative 6; Mismatches 19; Indels

QY 3 CWPQLRLMLKNTFFRRQ-----TCOLLEVAVPLFIFILISVRL 44
; : : : : : : : : : : : : : : : : : :
Db 369 CFHYTSTVLTSLAFQEQKLRCEQALQVAKNLFTHLDDVSLL 414
; : : : : : : : : : : : : : : : : : :

Search completed: May 31, 2001, 13:04:32
Job time: 2783 sec

```

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 31, 2001, 12:15:29 ; Search time 46.78 Seconds
(without alignments)
73.318 Million cell updates/sec

Title: US-09-526-193A-1_COPY_1_60

Perfect score: 334

Sequence: 1 MACWPQLRLLLNKNLTFRR.....SVRLSYPPYEQHECHFPNKA 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues

Total number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_0401.*
1: /SID56/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SID56/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SID56/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SID56/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SID56/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SID56/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SID56/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SID56/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SID56/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SID56/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SID56/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SID56/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SID56/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SID56/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SID56/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SID56/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SID56/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SID56/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SID56/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SID56/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SID56/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SID56/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	334	100.0	2143	21 B38108	Human ABC1 cholest
2	334	100.0	2259	21 B38107	Human ABC1 FHA-3 m
3	334	100.0	2260	21 B38106	Human ABC1 cholest
4	334	100.0	2261	21 B38082	Human ABC1 cholest
5	334	100.0	2261	21 B38104	Human ABC1 cholest
6	334	100.0	2261	21 B38105	Human ABC1 cholest
7	334	100.0	2261	21 B38109	Human ABC1 cholest
8	334	100.0	2261	21 B38110	Human ABC1 cholest
9	334	100.0	2261	21 B38111	Human ABC1 cholest
10	334	100.0	2261	21 B38112	Human ABC1 cholest
11	334	100.0	2261	21 B38113	Human ABC1 cholest

12	334	100.0	2261	21 B38114	Human ABC1 cholest
13	334	100.0	2261	21 B38115	Human ABC1 cholest
14	334	100.0	2261	21 B38116	Human ABC1 cholest
15	334	100.0	2261	21 B38117	Human ABC1 cholest
16	230	68.9	112	21 B41102	Human ORFX ORF866
17	180	53.9	2273	19 W70398	ATP binding cassette
18	117	35.0	21	21 B38083	Human ABC1 antigen
19	86	25.7	1704	19 W46771	Amino acid sequenc
20	60.5	18.1	502	20 Y49625	Corn hexose carrie
21	59.5	17.8	224	15 R53701	Sequence of castor
22	58.5	17.5	382	18 W31740	Delta-12 desaturas
23	58.5	17.5	4473	17 R97244	Virulence gene clu
24	58	17.4	382	20 W83353	Vernonia galamenen
25	57.5	17.2	255	21 Y70405	Class 1 fatty acid
26	56.5	16.9	272	21 Y83086	F-box protein FBP-
27	56.5	16.9	1387	21 Y95441	Caenorhabditis ele
28	56.5	16.9	1977	17 R95641	Peripheral nervous
29	56	16.8	373	20 Y30534	A G protein-couple
30	56	16.8	373	20 Y30538	A G protein-couple
31	56	16.8	373	21 Y71300	Human orphan G pro
32	56	16.8	373	21 B02834	Human 7TM receptor
33	56	16.8	373	21 Y32237	Human G protein co
34	56	16.8	610	20 Y35481	Chlamydia pneumoni
35	56	16.8	921	16 R69727	Cyclic-GMP stimula
36	56	16.8	921	18 W18048	Cyclic-GMP-stimula
37	56	16.8	921	18 W11252	Clone p3CGS-5 cycl
38	56	16.8	921	19 W71224	CGS-PDE encoded by
39	56	16.8	921	19 W77040	Adrenal cortex Ca2
40	56	16.8	921	19 W60752	CGS-PDE isolated f
41	56	16.8	921	21 Y80984	Bovine adrenal cor
42	56	16.8	941	13 R28409	Human foetal CGS P
43	56	16.8	941	16 R69729	Cyclic-GMP stimula
44	56	16.8	941	18 W18050	Human CGS-PDE amin
45	56	16.8	941	18 W11253	phc9s6n cyclic GMP

ALIGNMENTS

RESULT 1

B38108 ID B38108 standard; Protein; 2143 AA.

XX AC B38108;

XX DT 29-JAN-2001 (first entry)

XX DE Human ABC1 cholesterol transporter FHA-1 mutant protein (R21445STOP).

XX KW Human ABC1 cholesterol transporter; chromosome 9q31;

XX KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;

XX KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;

XX KW cardiovascular disease; coronary artery disease; coronary restenosis;

XX KW cerebrovascular disease; peripheral vascular disease;

XX KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;

XX KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

XX KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;

XX KW Homo sapiens.

XX OS WO200055318-A2.

XX PN 21-SEP-2000.

XX PD 15-MAR-2000; 2000WO-IB00532.

XX PF 15-MAR-1999; 99US-0124702.

XX PR 08-JUN-1999; 99US-0138048.

XX PR 17-JUN-1999; 99US-0139600.

XX PR 01-SEP-1999; 99US-0151977.

XX XX (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.
PI Hayden MR, Wilson AR, Pimstone SN;
XX WPI: 2000-587528/55.
DR N-PSDB; C69389.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
XX Sequence 2143 AA;
XX
XX Query Match 100.0%; Score 334; DB 21; Length 2143;
Best Local Similarity 100.0%; Pred. No. 2.6e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MACWPOLRLLLWNLTPRRQTCOLLLEAVPLFIFILILISVRLSYPPYQHECHFPNKA 60
Db 1 macwpqlrlllwnltfrrrtqcollleavplfifililsvrlsyppyeqhechfpnka 60
RESULT 2
B38107
ID B38107 standard; Protein: 2259 AA.
XX
AC B38107;
XX
XX 29-JAN-2001 (first entry)
DT
XX
XX Human ABC1 FHA-3 mutant protein (delta-E1893, D1894).

XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cerebrovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.
XX
XX Homo sapiens.
OS
XX
XX WO200055318-A2.
XX
XX 21-SEP-2000.
XX
XX 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
PA
XX Hayden MR, Wilson AR, Pimstone SN;
XX
XX WPI: 2000-587528/55.
XX N-PSDB; C69389.
XX
XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -
XX
XX Examples; Page -: 229pp; English.
XX
XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
XX Sequence 2143 AA;
XX
XX Query Match 100.0%; Score 334; DB 21; Length 2143;
Best Local Similarity 100.0%; Pred. No. 2.6e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MACWPOLRLLLWNLTPRRQTCOLLLEAVPLFIFILILISVRLSYPPYQHECHFPNKA 60
Db 1 macwpqlrlllwnltfrrrtqcollleavplfifililsvrlsyppyeqhechfpnka 60
RESULT 2
B38107
ID B38107 standard; Protein: 2259 AA.
XX
AC B38107;
XX
XX 29-JAN-2001 (first entry)
DT
XX
XX Human ABC1 FHA-3 mutant protein (delta-E1893, D1894).

CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 SQ Sequence 2259 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2259;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWKNLTFRRQTCQLLEVAWPLFLILISVRLSPYPYEQHECHFPNKA 60
 |||||
 Db 1 macwpqlrlllwknltfrrrtcqllleavawplfllilsvrlsypypyeqhechfpnka 60
 RESULT 3
 B38106
 ID B38106 standard; Protein; 2260 AA.
 XX
 AC B38106;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter PHA-1 mutant protein (delta-L693).
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.
 XX
 OS Homo sapiens.
 XX
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 PI Hayden MR., Willson AR, Pimstone SN;
 XX
 DR WPI: 2000-587528/55.
 DR N-PSDB; C69387.
 XX
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while

CC PHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX
 SQ Sequence 2260 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2260;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWKNLTFRRQTCQLLEVAWPLFLILISVRLSPYPYEQHECHFPNKA 60
 |||||
 Db 1 macwpqlrlllwknltfrrrtcqllleavawplfllilsvrlsypypyeqhechfpnka 60
 RESULT 4
 B38082
 ID B38082 standard; Protein; 2261 AA.
 XX
 AC B38082;
 XX
 DT 29-JAN-2001 (first entry)
 XX
 DE Human ABC1 cholesterol transporter.
 XX
 KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal.
 XX
 OS Homo sapiens.
 XX
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 PF 15-MAR-2000; 2000WO-IB00532.
 XX
 PR 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX

PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX (XENO-) XENON BIORESEARCH INC.
 PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI: 2000-587528/55.
 DR N-PSDB; C69120.
 DR
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Claim 5; Page 152-157; 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents the human ABC1 cholesterol transporter.
 XX
 SQ Sequence 2261 AA;
 Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWQQLRLLLWKNLFRFRRTQQLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60
 DQ 1 macwqqlrlllwknltfrfrtqqlleavawpfililslvrlsyppyeqhechfpnka 60
 RESULT 5
 ID B38104
 XX B38104 standard; Protein; 2261 AA.
 AC B38104;
 XX
 XX 29-JAN-2001 (first entry)
 DT
 XX Human ABC1 cholesterol transporter TD-1 mutant protein (C1477R).
 DE
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 CC

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 XX muten.
 OS Homo sapiens.
 XX OS
 PN WO200055318-A2.
 XX
 PD 21-SEP-2000.
 XX
 XX 15-MAR-2000; 2000WO-IB00532.
 PF
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX Hayden MR, Wilson AR, Pimstone SN;
 XX WPI: 2000-587528/55.
 DR N-PSDB; C69385.
 XX
 PT New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page : 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AJ012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.

Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNLTPRRROTCCOLLLEVAMPFLIFLILISVRLSPYPYQHECHFPNKA 60
|||||
Db 1 macwpqlrlllwnltprrrqcdllleavpflifllilsvrlsryppyeqhechfpnka 60
|||||

RESULT 7
B38109
ID B38109 standard; Protein; 2261 AA.
XX B38109;
XX
XX
XX 29-JAN-2001 (first entry)
XX
XX Human ABC1 cholesterol transporter mutant, R219K.
XX
XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muteln.
XX
XX Homo sapiens.
XX
XX WO20005318-A2.
XX
XX
XX 21-SEP-2000.
XX
XX 15-MAR-2000; 2000WO-IB00532.
XX
XX 15-MAR-1999; 99US-0124702.
XX 08-JUN-1999; 99US-0138048.
XX 17-JUN-1999; 99US-0139600.
XX 01-SEP-1999; 99US-0151977.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (XENO-) XENON BIORESEARCH INC.

XX Hayden MR, Wilson AR, Pimstone SN;
 PI WPI; 2000-587528/55.
 DR New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 XX Examples; Page -: 229pp; English.
 XX
 CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLILWKLTFRRRTQCLLEVAWPLFLILISVRLSYPPYQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqlrlilwklntfrfrrtqclllewawplfllilsvrlsyppqhechfpnka 60

RESULT 8

B38110

ID B38110 standard; Protein; 2261 AA.

XX AC B38110;

XX 29-JAN-2001 (first entry)

XX Human ABC1 cholesterol transporter mutant, V399A.

DE Human ABC1 cholesterol transporter; chromosome 9q31;

XX Human ABC1 cholesterol transporter; chromosome 9q31;

XX

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; Niemann-Pick disease;
 KW Alzheimer's disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.
 XX
 XX Homo sapiens.
 XX
 XX WO2000055318-A2.
 XX 21-SEP-2000.
 PD
 XX 15-MAR-2000; 2000WO-IB00532.
 XX
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 XX
 XX Hayden MR, Wilson AR, Pimstone SN;
 PI WPI; 2000-587528/55.

XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX
 PS Examples; Page -: 229pp; English.

XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNTFFRRQTCCLLLEVAWPLFLLILSVRLSYPPYEQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqrlrlllwknltffrrtccqllelvawplfllilsvrlsyppyeqhechfpnka 60

RESULT 9

B38111

ID B38111 standard; Protein; 2261 AA.

XX AC B38111;

XX DT 29-JAN-2001 (first entry)

XX DE Human ABC1 cholesterol transporter mutant, V771W.

XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.

XX OS Homo sapiens.

XX PN WO200055318-A2.

XX PD 21-SEP-2000.

XX PF 15-MAR-2000; 2000WO-IB00532.

XX PR 15-MAR-1999; 99US-0124702.

XX PR 08-JUN-1999; 99US-0138048.

XX PR 17-JUN-1999; 99US-0139600.

XX PR 01-SEP-1999; 99US-0151977.

XX PA (UYBR-) UNIV BRITISH COLUMBIA.

XX PA (XENO-) XENON BIORESEARCH INC.

PI Hayden MR, Wilson AR, Pimstone SN;

XX WPI; 2000-587528/55.

XX PT New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer.

XX PS Examples; Page 2; 229pp; English.

XX CC The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.

CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.

XX SQ Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLLLWKNTFFRRQTCCLLLEVAWPLFLLILSVRLSYPPYEQHECHFPNKA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1 macwpqrlrlllwknltffrrtccqllelvawplfllilsvrlsyppyeqhechfpnka 60

RESULT 10

B38112

ID B38112 standard; Protein; 2261 AA.

XX AC B38112;

XX DT 29-JAN-2001 (first entry)

XX DE Human ABC1 cholesterol transporter mutant, T774P.

XX KW Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutin.

XX OS Homo sapiens.

XX PN WO200055318-A2.

XX PD 21-SEP-2000.

XX PF 15-MAR-2000; 2000WO-IB00532.

XX PR 15-MAR-1999; 99US-0124702.

XX PR 08-JUN-1999; 99US-0138048.

XX PR 17-JUN-1999; 99US-0139600.

XX PR 01-SEP-1999; 99US-0151977.

XX PA (UYBR-) UNIV BRITISH COLUMBIA.

XX PA (XENO-) XENON BIORESEARCH INC.

PI Hayden MR, Wilson AR, Pimstone SN;
 XX WPI; 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX Examples; Page -: 229pp; English.
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX Sequence 2261 AA;
 SQ
 Query Match 100.0%; Score 334; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 2.7e-37;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MACWPQLRLLLWNLTPRRQTCOLLLEVAWPLFIFILISVRLSYPPYEQHECHFPNKA 60
 Db 1 macwplrlillwlnltfrrtqtcllleavawplfifillsvrlsyppyeqhechfpnka 60
 RESULT 11
 B38113
 ID B38113 standard; Protein; 2261 AA.
 XX B38113;
 AC B38113;
 XX 29-JAN-2001 (first entry)
 DT Human ABC1 cholesterol transporter mutant, K776N.
 DE Human ABC1 cholesterol transporter; chromosome 9q31;
 XX ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW

KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 XX mutuin.
 XX Homo sapiens.
 OS WO200055318-A2.
 XX 21-SEP-2000.
 PD 15-MAR-2000; 2000WO-IB00532.
 XX 15-MAR-1999; 99US-0124702.
 PR 08-JUN-1999; 99US-0138048.
 PR 17-JUN-1999; 99US-0139600.
 PR 01-SEP-1999; 99US-0151977.
 XX (UVBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON BIORESEARCH INC.
 PA Hayden MR, Wilson AR, Pimstone SN;
 PI WPI; 2000-587528/55.
 XX New ABC1 polypeptide is useful for treating diseases associated with
 PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 PT disease and cancer -
 XX Examples; Page -: 229pp; English.
 XX The invention relates to the human ABC1 cholesterol transporter protein
 CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 CC a member of the ATP-binding cassette (ABC transporter) superfamily of
 CC proteins, and plays a crucial role in cholesterol transport, particularly
 CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
 CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 CC located on chromosome 9q31, and mutations in this gene are associated
 CC with two genetic HDL (high density lipoprotein) deficiency disorders,
 CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 CC are distinguishable in that TD is an autosomal recessive disorder, while
 CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 CC cholesterol") in the blood correlate with a high risk of cardiovascular
 CC disease, particularly coronary artery disease, but also cerebrovascular
 CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 CC present sequence represents a mutant human ABC1 cholesterol transporter
 CC associated with an altered cholesterol level and therefore an altered
 CC risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is
 CC derived from the native human ABC1 shown on pages 152-157.
 XX

SQ Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLWKNLTFRRQTCOLLEAVWPLFIFLLISVRLSYPPYEQHECHFPNKA 60
|||||
DB 1 macwpqlrlwknltfrrrtcqllleavwplfifllisvrlsyppyeqhechfpnka 60

RESULT 12

B38114
ID B38114 standard; Protein; 2261 AA.

XX B38114;

XX 29-JAN-2001 (first entry)

XX Human ABC1 cholesterol transporter mutant, E1172D.

XX Human ABC1 cholesterol transporter; chromosome 9q31;

KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cerebrovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.

XX Homo sapiens.

XX WO2000055318-A2.

XX 21-SEP-2000.

XX 15-MAR-2000; 2000WO-IB00532.

XX 15-MAR-1999; 99US-0124702.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-0139600.

PR 01-SEP-1999; 99US-0151977.

XX (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX Hayden MR, Wilson AR, Pimstone SN;

XX WPI; 2000-587528/55.

XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -

PS Examples; Page -: 229pp; English.

XX The invention relates to the human ABC1 cholesterol transporter protein
CC (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against

CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC vector encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376.1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.
XX
SQ Sequence 2261 AA;

Query Match 100.0%; Score 334; DB 21; Length 2261;

Best Local Similarity 100.0%; Pred. No. 2.7e-37;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MACWPQLRLWKNLTFRRQTCOLLEAVWPLFIFLLISVRLSYPPYEQHECHFPNKA 60

DB 1 macwpqlrlwknltfrrrtcqllleavwplfifllisvrlsyppyeqhechfpnka 60

RESULT 13

B38115

ID B38115 standard; Protein; 2261 AA.

XX B38115;

XX 29-JAN-2001 (first entry)

XX Human ABC1 cholesterol transporter mutant, R1587K.

XX Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cerebrovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW muten.

XX Homo sapiens.

XX WO2000055318-A2.

XX 21-SEP-2000.

XX 15-MAR-2000; 2000WO-IB00532.

PR 15-MAR-1999; 99US-0124702.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-0139600.

PR 01-SEP-1999; 99US-0151977.

XX (UYBR-) UNIV BRITISH COLUMBIA.

PA (XENO-) XENON BIORESEARCH INC.

XX Hayden MR, Wilson AR, Pimstone SN;

PI

Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLLNKNTFRRTQTCQLLEVAWPLFLLISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqlrlllwknltfrtrtqcqllellevawplfllilsvrlsyppyeqhechfpnka 60

RESULT 15
B38117
ID B38117 standard; Protein: 2261 AA.
AC B38117;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human ABC1 cholesterol transporter mutant, I883M.
XX
KW Human ABC1 cholesterol transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
KW cardiovascular disease; coronary artery disease; coronary stenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW
XX
OS Homo sapiens.
XX
XX
FN WO200055318-A2.
XX
XX
PD 21-SEP-2000.
XX
XX
PF 15-MAR-2000; 2000WO-IB00532.
XX
XX
PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX
XX
PI Hayden MR, Wilson AR, Pimstone SN;
XX
XX
DR WPI; 2000-587528/55.
XX
XX
PT New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
XX disease and cancer -
XX
PS Examples; Page -: 229pp; English.
XX

The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary stenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and

transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary stenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AJ012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.

Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

Sequence 2261 AA;
Query Match 100.0%; Score 334; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 2.7e-37;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MACWPQLRLLLNKNTFRRTQTCQLLEVAWPLFLLISVRLSYPPYEQHECHFPNKA 60
|||||
Db 1 macwpqlrlllwknltfrtrtqcqllellevawplfllilsvrlsyppyeqhechfpnka 60

Search completed: May 31, 2001, 13:03:56
Job time: 2907 sec